Category: GlobeNewswire

  • MIL-OSI: BlackLine’s Signature Finance Transformation Event Returns to London and Debuts in Paris

    Source: GlobeNewswire (MIL-OSI)

    LONDON, June 11, 2025 (GLOBE NEWSWIRE) — BlackLine is expanding the reach of its flagship finance transformation event, BeyondTheBlack, with two key events in Europe this June. BeyondTheBlack will return to London on June 17, followed by its debut in Paris on June 19, marking the first time the event has been held in France.

    Each event brings together finance and accounting leaders across industries to explore how world-class companies are achieving smarter, faster, and more scalable financial operations through BlackLine’s AI-powered automation and platform innovation.

    Event Details:

    BEYONDTHEBLACK LONDON
    Date: June 17, 2025
    Location: De Vere Grand Connaught Rooms, London
    Details & Registration: beyondtheblack.com/london

    The London event will feature executive keynotes, live demos, and customer transformation stories from:

    • AstraZeneca
    • Hitachi
    • Kier Group
    • The LEGO Group

    BEYONDTHEBLACK PARIS
    Date: June 19, 2025
    Location: Cloud Business Center, Paris
    Details & Registration: beyondtheblack.com/paris

    Marking its debut in France, the Paris conference will be conducted in French and feature customer sessions from:

    • Hilti
    • Renault
    • Savencia

    Why Attend:

    • Explore BlackLine’s latest innovations, including the Studio360 platform
    • Hear directly from customers achieving meaningful business outcomes
    • Participate in deep-dive sessions led by BlackLine experts and partners
    • Connect with a community of finance leaders shaping the future of the Office of the CFO

    About BlackLine

    Companies come to BlackLine (Nasdaq: BL) because their traditional manual accounting processes are not sustainable. BlackLine’s cloud-based financial operations management platform and market-leading customer experience help companies move to modern accounting by unifying data, automating repetitive work, and driving accountability through visibility. BlackLine provides solutions to manage and automate financial close, intercompany accounting, invoice-to-cash, and consolidation processes—trusted by more than 4,400 customers worldwide, including 50% of the Fortune 500.

    For more information, visit www.blackline.com.

    Media Contact:

    Samantha Darilek
    VP, Corporate Communications
    samantha.darilek@blackline.com

    The MIL Network

  • MIL-OSI: BTCC Exchange Releases May 2025 Proof of Reserves Report: User Assets Secured at 152% Total Reserve Ratio

    Source: GlobeNewswire (MIL-OSI)

    VILNIUS, Lithuania, June 11, 2025 (GLOBE NEWSWIRE) — BTCC, the world’s longest-serving cryptocurrency exchange, has published its monthly Proof of Reserves (PoR) report for May 2025, demonstrating a robust 152% total reserve ratio and reinforcing its commitment to transparency and user asset security across all major asset holdings.

    The comprehensive audit, conducted on May 15, 2025, reveals that BTCC maintains substantial over-collateralization across all major crypto assets:

    • Bitcoin (BTC): 140%
    • Ethereum (ETH): 146%
    • Ripple (XRP): 165%
    • Tether (USDT): 150%
    • USD Coin (USDC): 164%
    • Cardano (ADA): 152%

    “Proof of Reserves is essential for building trust with our users and the broader market,” said Alex, Head of Operations at BTCC. “Our monthly report demonstrates that we maintain sufficient assets to fully cover all user deposits, reinforcing our commitment to fund security.”

    The May audit, conducted using Merkle Tree cryptography, enables users to independently verify their funds anytime on BTCC’s website using the latest Merkle root hash, with detailed verification instructions available.

    With reserve ratios exceeding 100% across all major cryptocurrencies, user assets are fully backed and over-collateralized, providing an additional security buffer that demonstrates BTCC’s commitment to fund protection.

    Since 2011, BTCC has maintained an impeccable security record throughout 14 years of operation. The regular monthly Proof of Reserves reporting demonstrates BTCC’s continued commitment to user fund security and transparency, setting a benchmark for responsible exchange operation in today’s rapidly changing crypto landscape.

    About BTCC Exchange

    Founded in 2011, BTCC is one of the world’s longest-serving cryptocurrency exchanges, offering secure and user-friendly trading services to millions of users globally. With a commitment to security, innovation, and community building, BTCC continues to be a trusted platform in the evolving cryptocurrency landscape.

    Website: https://www.btcc.com/en-US

    X: https://x.com/BTCCexchange

    Contact: press@btcc.com

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/88449014-8876-4578-acad-3252d6b91386

    The MIL Network

  • MIL-OSI: CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

    Source: GlobeNewswire (MIL-OSI)

    SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

    The reverse stock split will take effect at 12:01 a.m. Eastern Time on June 13, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) as of the opening of trading on June 13, 2025. The CUSIP number of 71902K402 will be assigned to the Company’s Common Stock when the reverse stock split becomes effective.

    When the reverse stock split becomes effective, every twenty (20) of the Company’s issued shares of Common Stock will be combined into one issued share of Common Stock, without any change to the par value per share. This will reduce the number of outstanding shares of Common Stock from approximately 10,321,839 shares to approximately 516,092 shares.

    Proportional adjustments will also be made to the number of shares of Common Stock awarded and available for issuance under the Company’s equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of the Company’s outstanding stock options and other equity securities under the Company’s equity incentive plans. Additionally, all outstanding shares of preferred stock will be adjusted in accordance with their terms, which will, among other changes to the preferred stock terms, result in proportionate adjustments being made to the number of shares issuable upon conversion of such preferred stock and to the conversion prices of such preferred stock. All outstanding warrants will also be adjusted in accordance with their terms, which will, among other changes to the warrant terms, result in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise and redemption prices of such warrants.

    No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fraction of a share of Common Stock of the Company will automatically be entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share.

    Stockholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the consequence of the reverse stock split reflected in their accounts on or after June 13, 2025. Such beneficial holders may contact their bank, broker, or nominee for more information.

    The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a reverse stock split authorized by the stockholders of the Company at the 2025 Annual Meeting of Stockholders of the Company held on May 29, 2025.

    About CERo Therapeutics Holdings, Inc.

    CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies.

    Forward-Looking Statements

    This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo the timing and completion of the reverse stock split, and the acceptance and implementation of its proposed plan of compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.

    Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025 and its subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Contact:
    Chris Ehrlich
    Chief Executive Officer
    cehrlich@cero.bio

    Investors:
    CORE IR
    investors@cero.bio

    The MIL Network

  • MIL-OSI: Zoom completes rollout of Zoom Phone in six telecom circles, with plans for further expansion in India

    Source: GlobeNewswire (MIL-OSI)

    SAN JOSE, Calif., June 11, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced the further expansion of its industry-leading Zoom Phone service to four major metro telecom circles in India — Mumbai, Delhi NCR, Karnataka (Bengaluru), and Andhra Pradesh & Telangana (Hyderabad). The Delhi NCR Telecom Circle includes the Union Territory of Delhi, Ghaziabad, Faridabad, NOIDA, and Gurgaon. Licensed by the Department of Telecommunications (DoT) India, Zoom Phone is now available in six telecom circles in India, including Maharashtra (October 2024) and Tamil Nadu (Chennai) Telecom Circles (February 2025), thereby covering key business and technology hubs in the country. Zoom also plans to bring Zoom Phone to additional telecom circles across India, accelerating its commitment to make AI-first modern telephony available to more organizations across key states in India.

    “Zoom Phone addresses the growing demand for cloud telephony by offering simplicity and modern functionality for distributed workforces. India is an important market for us, and our expansion plans beyond the six key telecom circles demonstrate our commitment to providing customers with a unified work platform. This expansion also reflects the growing traction Zoom Phone is receiving, especially from multinational companies, as businesses in India move away from legacy PBX systems toward more flexible, AI-first collaboration solutions that enhance employee productivity,” said Velchamy Sankarlingam, president of Product and Engineering, Zoom.

    Zoom Phone offers businesses simplicity and modern functionality, empowering dynamic workstyles and hybrid teams. Available as an add-on for existing paid Zoom customers, it supports inbound and outbound calling through the Public Switched Telephone Network (PSTN), enabling enterprises to replace legacy private branch exchange (PBX) systems and consolidate communication needs onto a single AI-first platform in Zoom Workplace.

    Zoom Phone also integrates seamlessly with Zoom Contact Center to offer a unified experience with features like call transfer, call forwarding, and call recording accessible within the Zoom Contact Center environment. Zoom Contact Center can access Zoom Phone user details like extensions, Direct Inward Dialing (DID) numbers, and usernames, enabling caller identification and routing.

    In addition to services in the six active telecom circles, Zoom Phone enables businesses to maintain seamless collaboration across India, even in regions where Zoom Phone service is not yet available. Through Zoom’s self-service web portal, customers can acquire native phone numbers based on specific telecom circles, such as Karnataka, Delhi NCR, and Mumbai, enabling them to establish a local presence in those regions. These native numbers operate over the PSTN, allowing customers to place outbound calls and receive inbound calls nationwide, regardless of their physical location. This allows organizations to maintain continuity and flexibility in their collaboration strategy, even in telecom circles where Zoom Phone is not directly available.

    Enhanced by Zoom AI Companion, which is included at no additional cost with eligible Zoom paid accounts, Zoom Phone offers powerful AI features to boost productivity. These include post-call summaries so users can focus on conversations instead of taking notes, voicemail task extraction to easily identify next steps, and voicemail prioritization to better manage time and attention. Zoom Phone also integrates seamlessly with Zoom Workplace, leading business applications, and hardware providers, offering robust security, scalability, and an intuitive user interface.

    “We are thrilled that Zoom Phone is now available in six of India’s most prominent business and technology hubs. Each of these cities is home to thriving ecosystems of local enterprises and multinational corporations that will benefit from Zoom Phone’s flexibility and seamless integration into their existing workflows. Bringing Zoom Phone to additional telecom circles is a natural next step in our commitment to empower more organizations with access to reliable, modern AI-first telephony,” said Sameer Raje, general manager and head of India & SAARC region at Zoom. “Zoom Phone and Zoom Contact Center are purpose-built to work seamlessly together to empower organizations to deliver unified communications and superior customer and employee engagement. With this launch, we are excited to help businesses streamline collaboration, support flexible workforces, and enhance employee and customer experiences.”

    To learn more about Zoom Phone, please visit the Zoom Phone page.

    About Zoom
    Zoom’s mission is to provide an AI-first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion that empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

    Zoom Press Contact
    Hayley Yap
    APAC Communications Lead
    press@zoom.us

    The MIL Network

  • MIL-OSI: Inception Growth Acquisition Limited Announces Extension of Business Combination Period

    Source: GlobeNewswire (MIL-OSI)

    New York, June 11, 2025 (GLOBE NEWSWIRE) — Inception Growth Acquisition Limited (NASDAQ: IGTA, the “Company”), a publicly traded special purpose acquisition company, announced today that at its annual meeting of stockholders on June 5, 2025 (the “Meeting”), the Company’s stockholders voted in favor of, among others, the proposals to amend (i) its amended and restated certificate of incorporation; and (ii) the investment management trust agreement with Continental Stock Transfer & Trust Company, giving the Company the right to extend the date on which to commence liquidating the trust account established in connection with the Company’s initial public offering (the “Trust Account”)  by four (4) times for an additional one (1) month each time from June 13, 2025 to October 13, 2025 by depositing into the trust account an aggregate amount equal to $0.075 multiplied by the number of common stock issued in the Company’s initial public offering that has not been redeemed for each one-month extension. The purpose of the extension is to provide additional time for the Company to complete a business combination.

    Contact

    Inception Growth Acquisition Limited
    Investor Relationship Department
    (315) 636-6638

    The MIL Network

  • MIL-OSI: Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company

    Source: GlobeNewswire (MIL-OSI)

    TORONTO, June 11, 2025 (GLOBE NEWSWIRE) — Apollo Technology Capital Corporation (“Apollo Capital”), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs”, or the “Company”), owning approximately 3% of the Company’s common stock, today issued a presentation to set forth their ambitious plan to grow your investment and help turn MediPharm around.

       
    • Outlines Commitment to Immediately and Aggressively Execute on Action Plan to 10X+ Share Price and Create Value for All Shareholders
    • Details Specific and Measurable Initiatives to Save MediPharm Labs from Insolvency at the Hands of Greedy, Reckless, and Maligned Leaders
    • Sets Forth Plan to Stop Exorbitant Executive Compensation Pay-for-Failure and End 3 Years of Value Destructive Actions
     
       

    THE TIME TO ACT IS NOW. VOTE THE GOLD CARD TODAY.

    SHAREHOLDERS ARE URGED TO PROTECT THEIR INVESTMENT BY VOTING THE GOLD PROXY CARD “FOR” APOLLO CAPITAL’S SIX HIGHLY-QUALIFIED DIRECTOR NOMINEES AND DISREGARD MEDIPHARM LABS’ GREEN PROXY CARD.

    TOGETHER LET’S SAVE MEDIPHARM AND DELIVER THE VALUE THAT SHAREHOLDERS DESERVE.

    View the Presentation at https://www.curemedipharm.com/historical-filing/investor-presentation.

    For more information on our detailed value creation plan and instructions on how to vote, please see our website www.curemedipharm.com.

    Contacts

    For Shareholders:
    Carson Proxy
    North American Toll-Free Phone: 1-800-530-5189
    Local or Text Message: 416-751-2066 (collect calls accepted)
    E: info@carsonproxy.com

    For Media:
    media@curemedipharm.com

    This solicitation is being made by and on behalf of Apollo Capital, who, as of the date of this Circular, beneficially owns or controls, directly and indirectly through its wholly-owned subsidiary, Nobul Technologies Inc., 12,491,500 common shares of the Company (“Common Shares”), representing approximately 3% of the total Common Shares issued and outstanding, and not by the management of the Company.

    Legal Disclosures

    Information in Support of Public Broadcast Exemption under Canadian Law

    In connection with the annual general and special meeting (the “Annual Meeting”) of shareholders of MediPharm, Apollo Capital has filed an amended and restated dissident information circular dated May 15, 2025 (the “Circular”), as amended and supplemented by an addendum to the Circular subsequently filed by Apollo Capital and Patrick McCutcheon (together, the “Concerned Stakeholder”) dated June 4, 2025 (the “Addendum” and together with the Circular, the “Amended Circular”), each in compliance with applicable corporate and securities laws. The Concerned Stakeholder has provided in, or incorporated by reference into, this press release the disclosure required under section 9.2(4) of NI 51-102 – Continuous Disclosure Obligations (“NI 51-102”) and the corresponding exemption under the Business Corporations Act (Ontario), and has filed the Amended Circular, available under MediPharm’s profile on SEDAR+ at www.sedarplus.ca. The Amended Circular contains disclosure prescribed by applicable corporate law and disclosure required under section 9.2(6) of NI 51-102 in respect of the Concerned Stakeholder’s director nominees, in accordance with corporate and securities laws applicable to public broadcast solicitations. The Amended Circular is hereby incorporated by reference into this press release and is available under MediPharm’s profile on SEDAR+ at www.sedarplus.ca. The registered office of the Company is 151 John Street, Barrie, Ontario, Canada L4N 2L1.

    SHAREHOLDERS OF MEDIPHARM ARE URGED TO READ THE AMENDED CIRCULAR CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION. Investors and shareholders are able to obtain free copies of the Amended Circular and any amendments or supplements thereto and further proxy circulars at no charge under MediPharm’s profile on SEDAR+ at www.sedarplus.ca. In addition, shareholders are also able to obtain free copies of the Amended Circular and other relevant documents by contacting the Concerned Stakeholder’s proxy solicitor, Carson Proxy Advisors Ltd. (“Carson Proxy”) at 1-800-530-5189, local (collect outside North America): 416-751-2066 or by email at info@carsonproxy.com. Finally, the Amended Circular is available on this website https://www.curemedipharm.com/historical-filing/investor-flyer.

    Proxies may be revoked in accordance with subsection 110(4) of the Business Corporations Act (Ontario) by a registered shareholder of Company shares: (a) by completing and signing a valid proxy bearing a later date and returning it in accordance with the instructions contained in the accompanying form of proxy; (b) by depositing an instrument in writing executed by the shareholder or by the shareholder’s attorney authorized in writing; (c) by transmitting by telephonic or electronic means a revocation that is signed by electronic signature in accordance with applicable law, as the case may be: (i) at the registered office of the Company at any time up to and including the last business day preceding the day the Annual Meeting or any adjournment or postponement of the Annual Meeting is to be held, or (ii) with the chair of the Annual Meeting on the day of the Annual Meeting or any adjournment or postponement of the Annual Meeting; or (d) in any other manner permitted by law. In addition, proxies may be revoked by a non-registered holder of Company shares at any time by written notice to the intermediary in accordance with the instructions given to the non-registered holder by its intermediary. It should be noted that revocation of proxies or voting instructions by a non-registered holder can take several days or even longer to complete and, accordingly, any such revocation should be completed well in advance of the deadline prescribed in the form of proxy or voting instruction form to ensure it is given effect in respect of the Annual Meeting.

    The costs incurred in the preparation and mailing of any circular or proxy solicitation by the Concerned Stakeholder and any other participants named herein will be borne directly and indirectly by Apollo Capital. However, to the extent permitted under applicable law, Apollo Capital intends to seek reimbursement from the Company of all expenses incurred in connection with the solicitation of proxies for the election of its director nominees at the Annual Meeting.

    This press release and any solicitation made by the Concerned Stakeholder is, or will be, as applicable, made by such parties, and not by or on behalf of the management of the Company. Proxies may be solicited by proxy circular, mail, telephone, email or other electronic means, as well as by newspaper or other media advertising and in person by managers, directors, officers and employees of the Concerned Stakeholder who will not be specifically remunerated therefor. In addition, the Concerned Stakeholder may solicit proxies by way of public broadcast, including press release, speech or publication and any other manner permitted under applicable Canadian laws, and may engage the services of one or more agents and authorize other persons to assist it in soliciting proxies on their behalf.

    Apollo Capital has entered into an agreement with Carson Proxy for solicitation and advisory services in connection with the solicitation of proxies by the Concerned Stakeholder for the Annual Meeting, for which Carson Proxy will receive a fee from Apollo Capital not to exceed $250,000, together with reimbursement for reasonable and out-of-pocket expenses. Apollo Capital has also engaged Gasthalter & Co. LP (“G&Co”) to act as communications consultant to provide the Concerned Stakeholder with certain communications, public relations and related services, for which G&Co will receive, from Apollo Capital, a minimum fee of US$75,000 in addition to a performance fee of US$250,000 in the event that the Concerned Stakeholder’s nominees make up a majority of the board of directors of MediPharm (the “Board”) following the Annual Meeting, plus excess fees, related costs and expenses.

    No member of the Concerned Stakeholder nor any of their respective associates or affiliates has or has had any material interest, direct or indirect, in any transaction since the beginning of the Company’s last completed financial year or in any proposed transaction that has materially affected or will or would materially affect the Company or any of the Company’s affiliates. No member of the Concerned Stakeholder nor any of their respective associates or affiliates has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Annual Meeting, other than setting the number of directors and the election of directors to the Board.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward‐looking statements. All statements contained in this filing that are not clearly historical in nature or that necessarily depend on future events are forward‐looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward‐looking statements. These statements are based on current expectations of the Concerned Stakeholder and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. All forward-looking statements contained herein are made only as of the date hereof and the Concerned Stakeholder disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which the Concerned Stakeholder hereafter becomes aware, except as required by applicable law.

    Hashtags: #ShareholderActivism #CorporateGovernance #InvestorProtection #Investor Alert #Investor Fraud #FinancialRegulation #CorporateCrime #FinancialCrime #HomelandSecurity #DHS #OpioidCrisis #OpioidEpidemic #OpioidLitigation #OpioidVictims #BMO #DEA #ONDCP

    The MIL Network

  • MIL-OSI: TruGolf Announces Acquisition of mlSpatial

    Source: GlobeNewswire (MIL-OSI)

    Salt Lake City, Utah, June 11, 2025 (GLOBE NEWSWIRE) — TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading golf technology company, has announced that it has executed a definitive agreement to acquire mlSpatial, a renowned AI and machine learning engineering firm. This strategic acquisition aims to advance the integration of artificial intelligence within TruGolf’s industry-leading products, including the Apogee Launch Monitor, Launchbox, Multisport Arcade, and E6 Apex.

    The collaboration between TruGolf and mlSpatial began in March 2024 with a licensing agreement to co-develop an AI engine enhancing the 9-axis spin accuracy of TruGolf’s Apogee Launch Monitor. Building upon this successful partnership, the full acquisition of mlSpatial will enable TruGolf to seamlessly incorporate advanced AI technologies across its entire product suite, delivering unparalleled user experiences, training suggestions, and player insights.

    “We are very excited to bring mlSpatial and its AI and machine learning technology into the TruGolf family,” said Chris Jones, TruGolf CEO. He continued, “Acquiring mlSpatial marks a significant milestone in our commitment to revolutionize golf simulation through cutting-edge AI integration. This acquisition empowers us to explore innovative applications of AI across our ecosystem, enhancing realism and interactivity for our users while lowering development costs.”

    Josh Pomazal, founder of mlSpatial, expressed enthusiasm about the acquisition: “We’re excited to leverage TruGolf’s extensive real-time data, collected daily, to continually refine our products with the advanced machine learning and AI models we’ve developed over the years.”

    This acquisition solidifies our deep commitment to innovation and aligns with the broader industry trend of significant investments in AI infrastructure. Notably, in January 2025, President Donald Trump announced a private-sector initiative, the Stargate Project, aiming to invest up to $500 billion in AI infrastructure within the United States. This substantial investment underscores the rapid progress and importance of AI technologies across various sectors.

    reuters.com

    TruGolf’s acquisition of mlSpatial positions the company at the forefront of AI-driven innovation in golf simulation, promising enhanced performance and immersive experiences for enthusiasts worldwide.

    For more information, please visit www.trugolf.com.

    About TruGolf Holdings

    TruGolf is a golf technology company, committed to making golf, easy. From innovative uses for AI to build content and enhance its image and spatial analysis, to gamified golf improvement plans, TruGolf is an industry leader in the growing technological revolution in the sport of golf. Since its founding, TruGolf has redefined what is possible in golf through technology. TruGolf’s suite of Hardware, Software, and Web Products make it easier to Play, Improve, and Enjoy the game of golf.

    Forward-Looking Statements

    Some of the statements in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements include, without limitation, whether the Company’s compliance plan will be accepted by Nasdaq and the Company’s expected future cash needs. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC’s website, www.sec.gov

    Media Contacts:

    TruGolf: Michael Bacal: Phone: 917-886-9071; mbacal@darrowir.com Web: TruGolf.com LinkedIn: @TruGolf

    The MIL Network

  • MIL-OSI: Siebert Financial Deepens Tech Strategy with FusionIQ Investment

    Source: GlobeNewswire (MIL-OSI)

    NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) — Siebert Financial Corp. (NASDAQ: SIEB) today announced a meaningful investment and strategic partnership with FusionIQ, a leading cloud-native digital wealth management platform. Under the agreement, Siebert will deploy FusionIQ’s technology to enhance its digital offerings and streamline end-to-end investment workflows across its growing client base.

    This move aligns with Siebert’s broader strategy to prioritize technology investment and forge strategic alliances to better serve its clients. The partnership enables Siebert to offer modular digital solutions that include hybrid advice, self-directed investing, and multi-custodian integration.

    “This partnership marks a pivotal step in reshaping our digital footprint,” said John J. Gebbia, Chief Executive Officer of Siebert Financial Corp. “It’s an investment that is positioning Siebert as a digital-first partner for the next generation of investors.”

    “We’re thrilled to integrate FusionIQ’s leading digital wealth management solutions with Siebert’s client offerings,” said John Kimbro, CTO of FusionIQ. “This partnership supports our shared mission to deliver financial freedom to everyone—through intuitive, scalable tools that meet each investor’s unique needs.”

    “Our partnership with Siebert Financial Corp. reflects a shared vision for the future of wealth management and investing tools—one that is inclusive, digital, and built for the next generation of investors,” said Eric Noll, CEO of FusionIQ. “With their forward-looking leadership and deep client relationships, Siebert is uniquely positioned to help us expand access to modern investing solutions. This is just the beginning—together, we’ll continue to broaden our reach, enhance our offerings, and redefine how wealth is built and managed in a digital-first world.”

    John M. Gebbia, Co-CEO of Muriel Siebert & Co. LLC, added, “We’re thrilled to integrate FusionIQ’s award-winning platform with Siebert. This collaboration accelerates our commitment to delivering personalized, tech-driven experiences to our client base. Our goal is clear: empower clients with tools that reflect today’s expectations and tomorrow’s ambitions.”

    About Siebert Financial Corp.
    Siebert is a diversified financial services company and has been a member of the NYSE since 1967, when Muriel Siebert became the first woman to own a seat on the NYSE and the first to head one of its member firms.

    Siebert operates through its subsidiaries Muriel Siebert & Co., LLC, Siebert AdvisorNXT, LLC, Park Wilshire Companies, Inc., RISE Financial Services, LLC, Siebert Technologies, LLC, and StockCross Digital Solutions, Ltd, and Gebbia Media LLC. Through these entities, Siebert provides a full range of brokerage and financial advisory services, including securities brokerage, investment advisory and insurance offerings, securities lending, and corporate stock plan administration solutions, in addition to entertainment and media productions. For over 55 years, Siebert has been a company that values its clients, shareholders, and employees. More information is available at www.siebert.com.

    Cautionary Note Regarding Forward-Looking Statements
    The statements contained in this press release that are not historical facts, including statements about our beliefs and expectations, are “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements preceded by, followed by, or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “estimate,” “target,” “project,” “intend” and similar words or expressions. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances are forward-looking statements.

    These forward-looking statements, which reflect beliefs, objectives, and expectations as of the date hereof, are based on the best judgment of the management of Siebert. All forward-looking statements speak only as of the date on which they are made. Such forward-looking statements are subject to certain risks, uncertainties and assumptions relating to factors that could cause actual results to differ materially from those anticipated in such statements, including, without limitation, the following: economic, social and political conditions, global economic downturns resulting from extraordinary events; securities industry risks; interest rate risks; liquidity risks; credit risk with clients and counterparties; risk of liability for errors in clearing functions; systemic risk; systems failures, delays and capacity constraints; network security risks; competition; reliance on external service providers; new laws and regulations affecting Siebert’s business; net capital requirements; extensive regulation, regulatory uncertainties and legal matters; failure to maintain relationships with employees, customers, business partners or governmental entities; the inability to achieve synergies or to implement integration plans; and other consequences associated with risks and uncertainties detailed in Part I, Item 1A – Risk Factors of Siebert’s Annual Report on Form 10-K for the year ended December 31, 2024, and Siebert’s filings with the SEC.

    Siebert cautions that the foregoing list of factors is not exclusive, and new factors may emerge, or changes to the foregoing factors may occur that could impact its business. Siebert undertakes no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise, except to the extent required by the federal securities laws.

    Media Contact:
    Deborah Kostroun, Zito Partners
    deborah@zitopartners.com
    +1 (201) 403-8185

    The MIL Network

  • MIL-OSI: Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

    Source: GlobeNewswire (MIL-OSI)

    PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) — FN Media Group News Commentary – The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates there will be over 35 million new cancer cases by 2050, a massive 77% increase from the estimated 20 million cases in 2022. This rising occurrence of cancer has been attributed to lifestyle changes in an increasingly geriatric population in both developed countries and emerging economies. Environmental factors such as pollution and the high penetration of microplastics, a potential carcinogen, are also contributing to the growing number of cancer cases. As the global burden of cancer continues to go up, government and private organizations are increasing funding in both healthcare infrastructure and investment into research and development of therapeutics and potential cures for various kinds of cancers. Many federal early detection programs have been launched with large players in the pharmaceutical sector looking to increase the number of clinical trials and drug discovery studies undertaken. These innovations are propelling market expansion, with the sector expected to witness significant growth in the coming years as new technologies and therapies continue to emerge. A new research report from BioSpace, said the global oncology market size was USD 321.19 billion in 2024, and calculated at USD 356.20 billion in 2025 is expected to reach around USD 903.81 billion by 2034, growing at a CAGR of 10.9% for the forecasted period. the development of the global healthcare infrastructure and cancer continuing to be one of the leading causes of death worldwide drives growth in the global oncology market. Active oncology biotech and pharma companies in the markets this week include Oncolytics Biotech®Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), BioNTech SE (NASDAQ: BNTX), Arvinas, Inc. (NASDAQ: ARVN), Pfizer Inc. (NYSE: PFE).

    The report said: “Innovations in cancer treatments include advancements in immunotherapy and precision medicine (which include targeted therapies), and the various applications of artificial intelligence. Some examples of novel oncological treatments include kinase and checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapy. These therapeutics mobilize the body’s immune system in new ways to fight cancer. As early diagnostic techniques improve, certain kinds of cancers, such as breast cancer, melanoma, and thyroid cancer, can be cured more frequently. Techniques such as liquid biopsy, biomarker-based testing and breakthroughs such as next-generation sequencing (NGS) are enhancing the ability to diagnose cancer at an early stage. As investment continues to grow in the oncology sector, new treatments are expected to improve the remission and survival rates of patients battling this disease and provide a boost to growth in the global oncology market.”

    Oncolytics Biotech®Inc. (NASDAQ: ONCY) (TSX: ONC) Names New CEO to Accelerate Momentum in Immunotherapy Programs — Oncolytics Biotech ® Inc., ($ONCY $ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a member of its Board of Directors.

    Mr. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy. Most recently, he played a central role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for $2 billion. Prior to Ambrx, he advised multiple leading-edge biotech companies on M&A and licensing transactions at highly respected law firms, including Lowenstein Sandler LLP and Kirkland & Ellis LLP. He is a JD and LLM graduate of Georgetown Law.

    “Mr. Kelly’s vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date,” said Wayne Pisano, Chair of Oncolytics’ Board of Directors and outgoing Interim CEO. “We believe Mr. Kelly’s well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics’ potential to deliver transformative outcomes for patients and exceptional value for investors.”

    Mr. Kelly added, “Pelareorep’s clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients. With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders.”

    Pelareorep, an intravenously-administered immunotherapeutic agent, has been granted FDA Fast Track designation by the U.S. Food and Drug Administration (FDA) in metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC). It has delivered compelling results in mPDAC, a high-value indication with significant unmet need. In Phase 1 and 2 trials involving more than 140 mPDAC patients, pelareorep has delivered a >60% objective response rate in tumor evaluable patients in the most recent study, which is more than double the benefit observed in historical control trials, and, separately, two-year survival rates 4-6 times those observed in control patients or against the benchmark in prior studies.

    In mBC, pelareorep recorded a meaningful survival benefit in two randomized Phase 2 studies of over 100 combined mBC patients, IND-213 and BRACELET-1. Phase 2 objective response rate data in second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA) patients continue to exceed historical data for treatment with a checkpoint inhibitor alone. These consistent efficacy signals, in combination with multiple chemotherapies and checkpoint inhibitors, uniquely position pelareorep as a high-potential asset for further development in-house and/or through strategic partnerships. Pelareorep also has a well-defined and favorable safety profile based on data from >1,100 patients across multiple tumor types.

    As a material inducement to Mr. Kelly’s appointment as Chief Executive Officer, and in accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Kelly has been awarded an initial stock option grant exercisable for 2,850,000 shares with an exercise price of CAD$0.57, vesting equally over three years. He also received a performance-based stock option grant exercisable for 1,900,000 shares with an exercise price of CAD$0.57, which will vest upon the achievement of certain financing objectives. All stock option grants have a term of 5 years from the date of grant. The Company also granted Mr. Kelly restricted stock units, which will entitle him to receive that number of Common Shares equal to 2% of the Company’s then outstanding common shares upon the Company entering into a definitive agreement for certain transactions providing for the acquisition of the Company or the exclusive license of pelareorep. Each of these awards is intended to align Mr. Kelly’s long-term incentives with the creation of shareholder value. CONTINUED Read these full press releases and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/

    Other recent oncology developments in the biotech industry of note include:

    Novartis AG (NYSE: NVS) recently announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3.

    Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile.

    BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb (BMY, “BMS”) recently announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.

    BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, including global Phase 3 trials with registrational potential evaluating BNT327 as first-line treatment in extensive stage small cell lung cancer (“ES-SCLC”) and non-small cell lung cancer (“NSCLC”). A global Phase 3 trial evaluating the candidate in triple negative breast cancer (“TNBC”) is planned to start by the end of 2025. Preliminary data from ongoing trials underscore the potential for combining anti-PD-L1 and anti-VEGF-A – two well-established therapeutic targets – into a single molecule to deliver synergistic clinical benefits for patients across multiple tumor types.

    Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) recently announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These data, which were highlighted in the American Society of Clinical Oncology (ASCO®) press briefing and selected for Best of ASCO, will be presented today in a late-breaking oral presentation (Abstract LBA1000) and have been simultaneously published in the New England Journal of Medicine.

    In the trial, vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) among patients with an estrogen receptor 1 (ESR1) mutation, reducing the risk of disease progression or death by 43% compared to fulvestrant [Hazard Ratio (HR)=0.57 (95% CI 0.42–0.77); 2-sided P<0.001]. The median PFS, as assessed by blinded independent central review (BICR), was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant. Investigator-assessed PFS was consistent with the BICR-assessed PFS. In patients with ESR1 mutations, vepdegestrant demonstrated a consistent PFS benefit over fulvestrant across all pre-specified subgroups. The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 for fulvestrant [HR=0.83 (95% CI 0.68–1.02); 2-sided P=0.07].

    About FN Media Group:

    At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies. #pressreleases #tickertagpressreleases

    Follow us on Facebook to receive emerging news updates: https://www.facebook.com/financialnewsmedia

    Follow us on Twitter for real time Breaking News: https://twitter.com/FNMgroup

    Follow us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/

    DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Oncolytics Biotech® Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

    This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

    Contact Information:

    Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757 

    SOURCE: FN Media Group

    The MIL Network

  • MIL-OSI: Draganfly Announces Pricing of US$13.75 Million Public Offering

    Source: GlobeNewswire (MIL-OSI)

    Saskatoon, SK., June 11, 2025 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), a drone solutions, and systems developer, today announced the pricing of its public offering (the “Offering”) of 5,500,000 units, with each unit consisting of one common share and one warrant to purchase one common share. Each unit is to be sold at a public offering price of US$2.50, for gross proceeds of approximately US$13.75 million, before deducting placement agent discounts and offering expenses. The warrants will have an exercise price of CA$5.0768 (or US$3.71) per share, are exercisable immediately and will expire five years following the date of issuance.

    Maxim Group LLC is acting as sole placement agent for the Offering.

    Draganfly currently intends to use the net proceeds from the Offering for general corporate purposes, including to fund its capabilities to meet demand for its new products including growth initiatives and/or for working capital requirements including the continuing development and marketing of the Company’s core products, potential acquisitions and research and development. The Offering is expected to close on or about June 12, 2025, subject to the satisfaction of customary closing conditions.

    The Offering is subject to customary closing conditions including receipt of all necessary regulatory approvals, including approval of the Canadian Securities Exchange and notification to the Nasdaq Stock Market.

    The Offering is being made pursuant to an effective shelf registration statement on Form F-10, as amended, (File No. 333-271498) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on July 5, 2023 and the Company’s Canadian short form base shelf prospectus dated June 30, 2023 (the “Base Shelf Prospectus”). Draganfly will offer and sell the securities in the United States only. No securities will be offered or sold to Canadian purchasers.

    A preliminary prospectus supplement and accompanying Base Shelf Prospectus relating to the Offering and describing the terms thereof has been filed with the applicable securities commissions in Canada and with the SEC in the United States and is available for free by visiting the Company’s profiles on the SEDAR+ website maintained by the Canadian Securities Administrators at www.sedarplus.ca or the SEC’s website at www.sec.gov, as applicable. A final prospectus supplement with the final terms will be filed with the securities regulatory authorities in the Canadian provinces of British Columbia, Saskatchewan and Ontario and the SEC. Copies of the preliminary prospectus supplements, accompanying Base Shelf Prospectus, and final prospectus supplement, when available, relating to the Offering may be obtained by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Draganfly

    Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) is a pioneer in drone solutions, AI-driven software, and robotics. With over 25 years of innovation, Draganfly has been at the forefront of drone technology, providing solutions for public safety, agriculture, industrial inspections, security, mapping, and surveying. The Company is committed to delivering efficient, reliable, and industry-leading technology that helps organizations save time, money, and lives.

    Media Contact
    media@draganfly.com

    Company Contact
    Email: info@draganfly.com

    Forward Looking Statements

    Certain statements contained in this news release may constitute “forward-looking statements” or “forward-looking information” within the meaning of applicable securities laws. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown. In this news release, such forward-looking statements include, but are not limited to, statements regarding the timing, size and expected gross proceeds of the Offering, the satisfaction of customary closing conditions related to the Offering and sale of securities, the intended use of proceeds, and Draganfly’s ability to complete the Offering. Closing of the Offering is subject to numerous factors, many of which are beyond Draganfly’s control, including but not limited to, the failure of the parties to satisfy certain closing conditions, and other important factors disclosed previously and from time to time in Draganfly’s filings with the securities regulatory authorities in the Canadian provinces of British Columbia, Ontario and Saskatchewan and with the SEC. Actual future events may differ from the anticipated events expressed in such forward-looking statements. Draganfly believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and Draganfly is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable securities laws.‎ Investors are cautioned not to unduly rely on these forward-looking statements and are encouraged to read the Offering documents, as well as Draganfly’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov/edgar.

    The MIL Network

  • MIL-OSI: Envoy Medical to Present at the Life Sciences Virtual Investor Forum June 12th

    Source: GlobeNewswire (MIL-OSI)

    WHITE BEAR LAKE, Minn., June 11, 2025 (GLOBE NEWSWIRE) — Envoy Medical®, Inc. (NASDAQ: COCH) (“Envoy Medical”), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear’s natural anatomy, today announced that Brent Lucas, CEO of Envoy Medical, will present live at the Life Sciences Virtual Investor Frum hosted by VirtualInvestorConferences.com, on June 12th, 2025.

    DATE: June 12th
    TIME: 3pm Eastern
    LINK: REGISTER HERE
    Available for 1×1 meetings: June 12th through the 17th

    This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

    It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.  

    Learn more about the event at www.virtualinvestorconferences.com.

    Recent Company Highlights

    • June 10, 2025 – Envoy Medical’s Pivotal Clinical Trial for Fully-Implanted Acclaim® Cochlear Implant On Track After First Month Follow Up
    • May 13, 2025 – Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    About Envoy Medical, Inc.

    Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

    About the Fully Implanted Acclaim® Cochlear Implant

    We believe the fully implanted Acclaim Cochlear Implant (“Acclaim CI”) is a first-of-its-kind hearing device. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The device is powered by a rechargeable battery and has an external charger to charge the internal device when necessary. In addition, patients are given an external remote or programmer to adjust settings or turn the device on or off.

    The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

    The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.

    For more information on the trial, investors can visit clinicaltrials.gov or www.envoymedical.com/acclaim-pivotal.

    CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

    About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)

    The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear’s natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can’t lose it. You don’t clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing. Patients are given an external remote or “personal programmer” to adjust volume, switch between hearing profiles, or turn the device on or off.

    Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.

    Additional Information and Where to Find It

    Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.

    Forward-Looking Statements
    This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the timing and results of IRB approvals, site documents, logistics or activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions or healthcare professionals in such trials; the Acclaim CI being the first to market fully implanted cochlear implant; the safety, performance, and market acceptance of the Acclaim CI; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical’s Class A Common Stock; changes in or removal of Envoy Medical’s shares inclusion in any index; Envoy Medical’s success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical’s key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical’s good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    CONTACTS:
    Envoy Medical Investor Contact
    Phil Carlson
    KCSA Strategic Communications
    212.896.1233
    Envoy@kcsa.com

    Virtual Investor Conferences
    John M. Viglotti
    SVP Corporate Services, Investor Access
    OTC Markets Group
    (212) 220-2221
    johnv@otcmarkets.com

    The MIL Network

  • MIL-OSI: Robinhood Markets, Inc. Reports May 2025 Operating Data

    Source: GlobeNewswire (MIL-OSI)

    MENLO PARK, Calif., June 11, 2025 (GLOBE NEWSWIRE) — Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported select monthly operating data for May 2025.

    • Funded Customers at the end of May were 25.9 million (up about 5 thousand from April 2025, up 1.8 million year-over-year). In May, Funded Customers grew by approximately 5 thousand after the impact of required escheatment of approximately 100 thousand low-balance accounts.
    • Total Platform Assets at the end of May were $255 billion (up 10% from April 2025, up 89% year-over-year). Net Deposits were $3.5 billion in May, or a 18% annualized growth rate relative to April 2025 Total Platform Assets. Over the last twelve months, Net Deposits were $59.1 billion, or an annual growth rate of 44% relative to May 2024 Total Platform Assets.
    • Equity Notional Trading Volumes were $180.5 billion (up 14% from April 2025, up 108% year-over-year). Options Contracts Traded were 179.8 million (up 7% from April 2025, up 36% year-over-year). Crypto Notional Trading Volumes were $11.7 billion (up 36% from April 2025, up 65% year-over-year).
    • Margin balances at the end of May were $9.0 billion (up 7% from the end of April 2025, up 100% year-over-year).
    • Total Cash Sweep balances at the end of May were $30.8 billion (up 7% from the end of April 2025, up 52% year-over-year).
    • Total Securities Lending Revenue in May was $33 million (up 32% from April 2025, up 43% year-over-year).
    • May 2025 results do not include the benefit of the Bitstamp acquisition which closed on June 2, 2025, including its approximately 500 thousand funded customers.
      May
    2025
    April
    2025
    M/M
    Change
    May
    2024
    Y/Y
    Change
    (M – in millions, B – in billions)          
    Funded Customer Growth (M)          
    Funded Customers 25.9 25.9 24.1 +7%
               
    Asset Growth ($B)          
    Total Platform Assets $255.3 $232.3 +10% $135.0 +89%
    Net Deposits1 $3.5 $6.8 NM $3.6 NM
               
    Trading          
    Trading Days (Equities and Options) 21 21 22 (5%)
    Total Trading Volumes          
    Equity ($B) $180.5 $157.8 +14% $86.8 +108%
    Options Contracts (M) 179.8 167.5 +7% 131.9 +36%
    Crypto ($B) $11.7 $8.6 +36% $7.1 +65%
               
    Daily Average Revenue Trades (DARTs) (M)
    Equity 2.3 2.3 2.0 +15%
    Options 1.2 1.2 0.8 +50%
    Crypto 0.5 0.5 0.3 +67%
               
    Customer Margin and Cash Sweep ($B)        
    Margin Book $9.0 $8.4 +7% $4.5 +100%
    Total Cash Sweep $30.8 $28.9 +7% $20.3 +52%
    Gold Cash Sweep $28.8 $26.9 +7% $19.6 +47%
    Non-Gold Cash Sweep $2.0 $2.0 $0.7 186%
               
    Total Securities Lending Revenue ($M) $33 $25 +32% $23 +43%

    Note: Does not reflect the acquisition of Bitstamp, which closed on June 2, 2025.

    1. Net Deposits do not include results from TradePMR.

    For definitions and additional information regarding these metrics, please refer to Robinhood’s full monthly metrics release, which is available on investors.robinhood.com.

    The information in this release is unaudited and the information for the months in the most recent fiscal quarter is preliminary, based on Robinhood’s estimates, and subject to completion of financial closing procedures. Final results for the most recent fiscal quarter, as reported in Robinhood’s quarterly and annual filings with the U.S. Securities and Exchange Commission (“SEC”), might vary from the information in this release.

    About Robinhood

    Robinhood Markets, Inc. (NASDAQ: HOOD) transformed financial services by introducing commission-free stock trading and democratizing access to the markets for millions of investors. Today, Robinhood lets you trade stocks, options, futures (which includes options on futures, swaps, and event contracts), and crypto, invest for retirement, and earn with Robinhood Gold. Headquartered in Menlo Park, California, Robinhood puts customers in the driver’s seat, delivering unprecedented value and products intentionally designed for a new generation of investors. Additional information about Robinhood can be found at www.robinhood.com.

    Robinhood uses the “Overview” tab of its Investor Relations website (accessible at investors.robinhood.com/overview) and its Newsroom (accessible at newsroom.aboutrobinhood.com), as means of disclosing information to the public in a broad, non-exclusionary manner for purposes of the SEC Regulation Fair Disclosure (Reg. FD). Investors should routinely monitor those web pages, in addition to Robinhood’s press releases, SEC filings, and public conference calls and webcasts, as information posted on them could be deemed to be material information.

    “Robinhood” and the Robinhood feather logo are registered trademarks of Robinhood Markets, Inc. All other names are trademarks and/or registered trademarks of their respective owners.

    Contacts

    Investor Relations
    ir@robinhood.com

    Media
    press@robinhood.com

    The MIL Network

  • MIL-OSI: Aterian’s PurSteam and Mueller Living Brands Launch Products in Walmart Stores

    Source: GlobeNewswire (MIL-OSI)

    SUMMIT, N.J., June 11, 2025 (GLOBE NEWSWIRE) — Aterian, Inc. (Nasdaq: ATER), a consumer products company, today announced the national launch of two of its most innovative home appliances – the PurSteam Steam Station Max and the Mueller Living Cordless Portable Vacuum Sealer – now available nationwide across Walmart locations.

    “These launches reflect Aterian’s broader mission to expand our omni-channel presence by bringing high-quality consumer products to both digital and physical retail platforms,” said Arturo Rodriguez, Chief Executive Officer of Aterian. “The increased brand visibility, coupled with mass-market accessibility, is designed to strengthen the Company’s growth trajectory and retail partnerships.”

    Product Launch Descriptions

    • The PurSteam Steam Station Max delivers premium ironing performance at an accessible price point. Featuring rapid 1.5-minute preheat, strong continuous steam output, and a large 50.7 oz water tank, it’s built for speed and convenience. A ceramic soleplate ensures smooth gliding across all fabrics, while integrated anti-calc, anti-drip, and auto shut-off features enhance safety and extend appliance life.
    • Also launching is the Mueller Living Cordless Portable Vacuum Sealer, a compact, high-performance food preservation tool that seals up to 60 bags on a single charge. With universal compatibility, fast 3-hour charging, and a cordless design, it’s ideal for everyday kitchens, meal prepping, or on-the-go storage.

    “Whether it’s the commercial-grade power of our PurSteam Steam Station Max or the flexible, space-saving design of our Mueller Living Cordless Portable Vacuum Sealer, our goal is to deliver intelligent products that make life at home better,” Mr. Rodriguez continued. “These launches exemplify our commitment to combining thoughtful design with the power, safety, and everyday convenience that households demand.”

    About PurSteam
    PurSteam, an Aterian brand, is dedicated to revolutionizing the way people clean and care for their homes. From high-performance steam irons to state-of-the-art steam mops, PurSteam delivers products that combine advanced technology, superior quality, and exceptional value. To learn more, visit www.pursteam.com.

    About Mueller Living
    Mueller Living, part of the Aterian brand portfolio, believes the kitchen is the heart of the home. Known for its premium, affordable kitchen tools, Mueller Living inspires cooks of all levels with products that blend comfort, design, and durability. To learn more, visit www.muellerliving.com.

    About Aterian, Inc.
    Aterian, Inc. (Nasdaq: ATER) is a technology-enabled consumer products company that builds and acquires leading e-commerce brands across multiple categories, including home and kitchen appliances, health and wellness, and air quality devices. The Company sells across the world’s largest online marketplaces, including Amazon, Walmart, and Target as well as its own direct-to-consumer websites. Aterian’s brands include Mueller Living, PurSteam, hOmeLabs, Squatty Potty, Healing Solutions, and Photo Paper Direct. To learn more, visit www.aterian.io.

    Forward Looking Statements
    All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, our ability to expand our omni-channel presence, and strengthen our growth trajectory and retail partnerships. These forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties and other factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to our ability to continue as a going concern, the effect of tariffs and other costs on our results, our ability to continue to operate following our reduction in workforce, our ability to meet financial covenants with our lenders, our ability to maintain and to grow market share in existing and new product categories; our ability to continue to profitably sell the SKUs we operate; our ability to maintain Amazon’s Prime badge on our seller accounts or reinstate the Prime badge in the event of any removal of such badge by Amazon; our ability to create operating leverage and efficiency when integrating companies that we acquire, including through the use of our team’s expertise, the economies of scale of our supply chain and automation driven by our platform; those related to our ability to grow internationally and through the launch of products under our brands and the acquisition of additional brands; those related to consumer demand, our cash flows, financial condition, forecasting and revenue growth rate; our supply chain including sourcing, manufacturing, warehousing and fulfillment; our ability to manage expenses, working capital and capital expenditures efficiently; our business model and our technology platform; our ability to disrupt the consumer products industry; our ability to generate profitability and stockholder value; international tariffs and trade measures; inventory management, product liability claims, recalls or other safety and regulatory concerns; reliance on third party online marketplaces; seasonal and quarterly variations in our revenue; acquisitions of other companies and technologies and our ability to integrate such companies and technologies with our business; our ability to continue to access debt and equity capital (including on terms advantageous to the Company) and the extent of our leverage; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), all of which you may obtain for free on the SEC’s website at www.sec.gov.

    Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

    Investor Contact:

    The Equity Group
    Devin Sullivan, Managing Director
    dsullivan@theequitygroup.com

    Conor Rodriguez, Associate
    crodriguez@theequitygroup.com

    The MIL Network

  • MIL-OSI: AMSC Announces Pricing of $115 Million Public Offering of Common Stock

    Source: GlobeNewswire (MIL-OSI)

    AYER, Mass., June 11, 2025 (GLOBE NEWSWIRE) — American Superconductor Corporation (Nasdaq: AMSC), a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid™ and protect and expand the capability and resiliency of our Navy’s fleet, announced today that it has priced its underwritten public offering of 4,125,000 shares of its common stock at a public offering price of $28.00 per share. AMSC expects the gross proceeds from this offering to be $115,500,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. AMSC intends to use the net proceeds from this offering for working capital and general corporate purposes, including potential strategic acquisitions. AMSC has granted the underwriters a 30-day option to purchase up to 618,750 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. AMSC expects to close the offering, subject to customary conditions, on or about June 12, 2025.

    Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering. Craig-Hallum Capital Group LLC is acting as lead manager and Roth Capital Partners is acting as co-manager for the offering.

    A shelf registration statement relating to the shares of common stock to be issued in the proposed offering was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and a final prospectus supplement will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available, from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8563, or by email at EquityProspectus@opco.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, among other things, statements regarding the completion of the offering, the expected gross proceeds therefrom, the intended use of net proceeds therefrom, and other statements containing the words “intends,” “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions. Such forward-looking statements represent management’s current expectations and are inherently uncertain. There are a number of important factors that could materially impact the value of AMSC’s common stock or cause actual results to differ materially from those indicated by such forward-looking statements. These important factors include, but are not limited to: the risk and uncertainties associated with market conditions, satisfaction of customary closing conditions related to the public offering, as well as risks and uncertainties in AMSC’s business, including those risks discussed in the “Risk Factors” section in the preliminary prospectus supplement related to the offering and in Part I, Item 1A of AMSC’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025 and AMSC’s other reports filed with the SEC. These important factors, among others, could cause actual results to differ materially from those indicated by forward-looking statements made herein and presented elsewhere by management from time to time. Any such forward-looking statements represent management’s estimates as of the date of this press release. While AMSC may elect to update such forward-looking statements at some point in the future, AMSC disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing its views as of any date subsequent to the date of this press release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Contacts

    Nicol Golez
    Phone: 978-399-8344
    Nicol.Golez@amsc.com 

    Investor Relations
    Carolyn Capaccio
    (212) 838-3777
    amscIR@allianceadvisors.com

    Public Relations
    RooneyPartners
    Joe Luongo
    (914) 906-5903
    jluongo@rooneypartners.com 

    The MIL Network

  • MIL-OSI: Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th

    Source: GlobeNewswire (MIL-OSI)

    TORONTO, June 11, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on June 12th, 2025

    DATE: June 12th
    TIME: 2:00 PM ET
    LINK: REGISTER HERE

    This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

    It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

    Learn more about the event at www.virtualinvestorconferences.com.

    Recent Company Highlights

    • Upsized $20 million CAD financing led by U.S. institutional investors is expected to support finalizing product development of the next-generation Novasight Hybrid system, submit for regulatory clearance and enable commercial launch
    • New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight’s unique value proposition
    • U.S. FDA 510(k) submission remains on track for calendar Q3 2025

    About Conavi Medical
    Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare. For more information, visit conavi.com.

    About Virtual Investor Conferences®
    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access.  Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Forward-Looking Statements
    This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the April 2025 public offering, Conavi’s exposure to the U.S. investment community, the commercialization and development of the Novasight Hybrid System and the achievement and timeline of key milestones towards commercialization and development of the Novasight Hybrid System. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” “anticipate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company’s profile at sedarplus.ca ). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
    No regulatory authority has approved or disapproved the content of this press release.
    Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

    Contacts:

    Conavi Medical
    Stefano Picone
    Chief Financial Officer
    ir@conavi.com
    (416) 483-0100

    Virtual Investor Conferences
    John M. Viglotti
    SVP Corporate Services, Investor Access
    OTC Markets Group
    (212) 220-2221
    johnv@otcmarkets.com

    The MIL Network

  • MIL-OSI: Vietnam Enterprise Investments Limited (VEIL) – Vietnam Forum & Annual General Meeting 2025

    Source: GlobeNewswire (MIL-OSI)

    LONDON, June 11, 2025 (GLOBE NEWSWIRE) — We are pleased to invite you to the Annual General Meeting (AGM) of Vietnam Enterprise Investments Limited (VEIL), taking place at 12:00 PM (UK time) on 18 June 2025 at The Stationers’ Hall, Ave Maria Lane, London EC4M 7DD, United Kingdom.

    The meeting will be chaired by Sarah Arkle, Chair of VEIL, and will include a presentation on Vietnam’s dynamic economic landscape by Dominic Scriven, Chair of Dragon Capital Group. Following this, Tuan Le, VEIL’s Lead Portfolio Manager, will provide an update on the fund’s performance and the outlook for Vietnam’s stock market.

    After the formal proceedings and Q&A session, we warmly invite you to join us for a Vietnamese buffet lunch at 1:15 PM, offering a wonderful opportunity to connect with fellow investors and industry experts.

    A Key Vote on VEIL’s Future
    This year’s AGM includes a vote on the Trust’s continuation. Given Vietnam’s strong domestic growth, ongoing government reforms, and compelling long-term potential, the Board believes VEIL is well-positioned for the future and recommends shareholders vote against discontinuation. We encourage all shareholders to participate in this important decision.

    Who Should Attend?
    The event is open to existing VEIL shareholders as well as those interested in learning more about investment opportunities in Vietnam. If you have colleagues who may wish to attend, please feel free to share this invitation and direct them to register via the link below.

    Register Here: https://www.veil.uk/2025-annual-general-meeting/

    We look forward to welcoming you for an engaging and informative afternoon.

    For further information or interview requests, please contact:

    Rachel Hill
    +44 (0) 797 121 4852
    rachelhill@dragoncapital.com 

    Thuy Anh Nguyen
    +44 (0) 788 588 6492
    thuyanhnguyen@dragoncapital.com 

    Steven Mantle
    +44 (0) 755 370 1237
    stevenmantle@dragoncapital.com 

    Jefferies International Limited
    Stuart Klein
    +44 (0) 20 7029 8703
    stuart.klein@jefferies.com 

    h2Radnor
    Iain Daly
    +44 (0) 20 3897 1830
    idaly@h2radnor.com 

    About VEIL

    Vietnam Enterprise Investments Limited (VEIL) is a closed-end fund listed on the London Stock Exchange and one of the longest-running and largest funds focused on Vietnam. Since its launch in 1995, VEIL has invested in high-growth, well-governed Vietnamese companies, offering investors exposure to the country’s vibrant economy.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60b54085-a65b-405e-9930-6457c4e0e889

    The MIL Network

  • MIL-OSI: Texas Holds Three of the Top Five Destination Cities for Consumer Migration

    Source: GlobeNewswire (MIL-OSI)

    CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) — Americans who relocated in 2024 sought out new locales, with the three most popular locations in the state of Texas—North Houston, Fort Worth and Austin. Overall, consumers left pricier and densely populated urban areas in favor of more affordable cities and suburbs in the southern U.S., according to TransUnion (NYSE: TRU) research focused on migration and its implications for insurers.

    While migration rates have decreased steadily since pre-pandemic 2019, a significant number of consumers are making bold moves. More than a quarter (26%) of Americans who moved in 2024 relocated by distances ranging from 51 miles to 250 miles and beyond.

    “As consumers continue to find new places to settle, it’s important for insurers to stay on top of the trends across segments,” said Patrick Foy, senior director of strategic planning for TransUnion’s Insurance business. “These changes can have implications for customer acquisition, risk and engagement.”

    Top Five Inbound and Outbound Markets in 2024

    Inbound Outbound
    North Houston, TX Miami, FL
    Fort Worth, TX Houston, TX
    Austin, TX Queens, NY
    Phoenix, AZ South Florida, FL
    Nashville, TN Oakland, CA


    Gen Z goes against the grain

    The research found migration trends among consumers aged 30 and older largely held true. The majority left locales like New York, Chicago and Miami, with some slight variations in where they ended up. Baby Boomers and Silent Generation consumers primarily moved to smaller locales in South Carolina and Florida. Gen Xers also moved to those states, but Texas was their top destination. Millennials seemed to avoid Florida, instead dispersing across suburban markets Texas and North Carolina.

    However, many Gen Z consumers moved in the opposite direction, landing in the same cities older Americans were leaving, like New York and Chicago.

    “Gen Z’s migration patterns more closely reflect those of Millennials back in 2010,” said Foy. “And they are likely going for the same reasons: the allure of big city living and the prospect of work opportunities to help launch their careers.”

    Staying connected to life insurance beneficiaries
    When consumers move across state lines, public records do not always update accordingly. This can create problems for life insurance providers who then may not be able to locate a beneficiary or receive notification of death for their policyholder.

    The majority of states require life insurers to monitor mortality status of policy holders and to conduct due diligence to contact beneficiaries. However, over recent years the federal government has limited access to the Social Security Death Master File (SS DMF). Those records now account for only 12% of TransUnion’s deceased file data—compared to 2010 when they accounted for 95%. 

    Additionally, nearly six out of 10 consumers don’t even know how to find out if they are the beneficiary of a life insurance policy. This is underscored by the fact that each year tens of millions of dollars in life insurance payments go unmatched with beneficiaries.1

    TransUnion’s TruLookup™ Deceased Data utilizes multiple sources, including TransUnion proprietary data, obituary data, funeral home listings, state level sources, and more. Insurers who rely solely on the SS DMF are at a significant disadvantage for uniting benefits to beneficiaries.

    “Life insurance companies that rely on public records alone will likely fail to deliver on their promise to customers,” said Karen Malone, senior director of strategic planning for TransUnion’s life insurance business. “They need a robust identity solution to give them real time updates on the status of their insureds and the location of their beneficiaries.”

    Understanding a driver’s risk
    Similarly, when a consumer with prior traffic violations moves to a new state or receives a traffic violation outside of their license state, their motor vehicle report (MVR) does not always capture those events.

    Prior TransUnion research found that violations increased by 8% in 2024 compared to 2023—their highest point since the onset of the coronavirus pandemic. The study highlighted the strong correlation between traffic enforcement and roadway safety, along with reaffirming the power of violation data to predict future insurance losses.

    TransUnion research notes that auto insurers should look beyond MVRs and investigate court records when assessing the risk of a new customer as they are less expensive than MVRs and provide a more comprehensive history. In addition, traffic violations have reached their highest point since the onset of the coronavirus pandemic, suggesting there are increasingly more insights into drivers’ behavior on the road.

    Learn more about TransUnion Insurance Risk solutions, including TruVision™ Driving History, here.
    Learn more about TransUnion solutions for life insurance here.

    1. “What to Know About Life Insurance Beneficiaries,” National Association of Insurance Commissioners, September 12, 2023

    About TransUnion (NYSE: TRU)
    TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world. http://www.transunion.com/business

    Contact Dave Blumberg
    TransUnion
       
    E-mail david.blumberg@transunion.com
       
    Telephone 312-972-6646

    The MIL Network

  • MIL-OSI: NextNRG to Be Added to Russell 2000® and Russell 3000® Indexes

    Source: GlobeNewswire (MIL-OSI)

    MIAMI, June 11, 2025 (GLOBE NEWSWIRE) — NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI-powered energy innovation, today announced its inclusion in the Russell 2000® and Russell 3000® Indexes, according to a list of additions published by FTSE Russell. The Company leverages advanced technologies—including its Next Utility Operating System®, smart microgrid infrastructure, wireless EV charging, and on-demand mobile fuel delivery—to transform how energy is produced, managed, and delivered.

    The official reconstitution will take effect after market close on Friday, June 27, 2025. Trading in the reconstituted indexes will begin on Monday, June 30, 2025.

    The Russell indexes are widely used by investment managers and institutional investors for index-based funds and benchmarking. FTSE Russell estimates that approximately $10.6 trillion in assets are benchmarked to the Russell U.S. indexes.

    “This recognition marks an important milestone in our continued growth,” said Michael D. Farkas, Founder and CEO of NextNRG. “We believe that inclusion in the Russell indexes reflects our disciplined execution and growing investor recognition of NextNRG’s unique position at the convergence of efficient energy, intelligent mobility, and AI-powered infrastructure. As we scale transformative projects across the country, this expanded visibility will support deeper institutional engagement and long-term value creation.”

    The Russell index reconstitution ranks the 3,000 largest U.S. stocks by total market capitalization. Companies included in the all-cap Russell 3000® Index are automatically assigned to the large-cap Russell 1000® or small-cap Russell 2000® Index, as well as relevant growth and value indexes.

    NextNRG’s addition to the Russell indexes follows strong quarterly growth and strategic progress across key markets, including new state expansion, enterprise partnerships, and continued advancement of its proprietary energy infrastructure platform.

    About NextNRG, Inc.
    NextNRG Inc. (NextNRG) is Powering What’s Next by implementing artificial intelligence (AI) and machine learning (ML) into renewable energy, next-generation energy infrastructure, battery storage, wireless electric vehicle (EV) charging and on-demand mobile fuel delivery to create an integrated ecosystem.

    At the core of NextNRG’s strategy is its Next Utility Operating System®, which leverages AI and ML to help make existing utilities’ energy management as efficient as possible; and the deployment of NextNRG smart microgrids, which utilize AI-driven energy management alongside solar power and battery storage to enhance energy efficiency, reduce costs and improve grid resiliency. These microgrids are designed to serve commercial properties, healthcare campuses, universities, parking garages, rural and tribal lands, recreational facilities, and government properties, expanding energy accessibility while supporting decarbonization initiatives.

    NextNRG continues to expand its growing fleet of fuel delivery trucks and national footprint, including the acquisition of Yoshi Mobility’s fuel division and Shell Oil’s trucks, further solidifying its position as a leader in the on-demand fueling industry. NextNRG is also integrating sustainable energy solutions into its mobile fueling operations. The company hopes to be an integral part of assisting its fleet customers in their transition to EV, providing fuel delivery while advancing efficient energy adoption. The transition process is expected to include the deployment of NextNRG’s innovative wireless EV charging solutions.

    To find out more visit: www.nextnrg.com

    Forward-Looking Statements
    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement describing NextNRG’s goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “expect,” “intends,” “will,” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including, but not limited to, those related to NextNRG’s business and macroeconomic and geopolitical events. These and other risks are described in NextNRG’s filings with the Securities and Exchange Commission from time to time. NextNRG’s forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although NextNRG’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by NextNRG. Except as required by law, NextNRG undertakes no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.

    Investor Relations Contact
    NextNRG, Inc.
    Sharon Cohen
    SCohen@nextnrg.com

    The MIL Network

  • MIL-OSI: Founder Group Secures Additional Contracts with Solar Installation Companies in Malaysia of US$ 1.5 Million

    Source: GlobeNewswire (MIL-OSI)

    KUALA LUMPUR, Malaysia, June 11, 2025 (GLOBE NEWSWIRE) — Founder Group Limited (NASDAQ: FGL) (“Founder Group” or the “Company”), a leading engineering, procurement, construction, and commissioning (EPCC) solutions provider for solar photovoltaic (PV) systems in Malaysia, is pleased to announce that it has secured additional contracts with prominent solar installation companies in Malaysia.

    The Company secured a contract totaling RM3.4 million (approximately US$806,193) engineering, procurement, construction, and commissioning contract for the development of a 29.99 megawatt (MWac) large-scale solar (LSS) photovoltaic plant in Bukit Badong, Selangor. The Founder Group will be responsible for the mechanical and wiring of the facility.

    Further, the Company secured an additional contract valued at RM2.8 million (approximately US$662,452) from the same business that Founder Group contracted with on a previous solar PV project deal which was announced earlier in the year. The business that the Company contracted with has a solid track record in the industry focusing in investment of renewable energy assets throughout Malaysia.

    This partnership with two prominent industry players will be a construction contract that is expected to be completed this year. Founder Group has secured contracts with this solar installation company for similar types of facilities and expects additional contracts from them over the next few years.

    For one of the projects, Founder Group will serve as a contractor, responsible for the design, engineering, procurement, construction and commissioning of a roof-top solar PV generating facility with nominal capacity.

    “We are excited about the continued momentum in securing additional contracts which have been a combination of brand-new partnerships and additional contract wins from our current collaborative business customers. Our latest contracts will be instrumental in enhancing Founder Group’s revenue growth, operational capabilities, and ability to expand our footprint in the Malaysian market. Additionally, we look forward to building solid relationships with premiere companies in the industry that are growing in the region and share the same vision of working together to support the country’s renewable energy goals and focused on promoting a greener, more sustainable future,” said Lee Seng Chi, Chief Executive Officer of Founder Group Limited.

    About Founder Group Limited

    Founder Group Limited is a pure-play, end-to-end EPCC solutions provider for solar PV facilities in Malaysia. The company’s primary focus is on two key segments: large-scale solar projects and commercial and industrial (C&I) solar projects. The company’s mission is to provide customers with innovative solar installation services, promote eco-friendly resources and achieve carbon-neutrality.

    For more information on the Company, please visit https://www.founderenergy.com.my/.

    Safe Harbor Statement

    This press release contains forward-looking statements that reflect our current expectations and views of future events. Known and unknown risks, uncertainties and other factors, including those listed under “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements involve various risks and uncertainties. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. We qualify all of our forward-looking statements by these cautionary statements.

    CONTACT INFORMATION:

    For media queries, please contact:
    Founder Group Limited info@founderenergy.com.my

    Investor Relations Inquiries:

    Skyline Corporate Communications Group, LLC
    Scott Powell, President
    1177 Avenue of the Americas, 5th Floor
    New York, New York 10036
    Office: (646) 893-5835
    Email: info@skylineccg.com

    The MIL Network

  • MIL-OSI: Mercurity Fintech Announces $800 Million Financing Plan for Bitcoin Treasury; Achieves Preliminary Inclusion in the U.S. Russell 2000 Index

    Source: GlobeNewswire (MIL-OSI)

    New York, NY, June 11, 2025 (GLOBE NEWSWIRE) — Mercurity Fintech Holding Inc. (the “Company,” “we,” “us,” “our company,” or “MFH”) (Nasdaq: MFH), a digital fintech group, today announced its plans to raise $800 million to establish a long-term Bitcoin treasury reserve. Through this fundraising effort, MFH aims to leverage its established expertise in blockchain-driven financial infrastructure to strategically acquire and manage Bitcoin assets. The Company also plans to integrate these holdings into its digital reserve framework through blockchain-native custody, staking integration, and tokenized treasury management services.

    Additionally, through this fundraising effort, the Company intends to systematically build a Bitcoin reserve position and implement an integrated digital asset treasury framework. This will involve deploying institutional-grade custodial infrastructure, blockchain-native liquidity protocols, and staking-enabled capital efficiency tools. The objective is to transition a portion of the Company’s treasury into a yield-generating, blockchain-aligned reserve structure that reinforces long-duration asset exposure and balance sheet resilience.

    “We’re building this Bitcoin treasury reserve based on our belief that Bitcoin will become an essential component of the future financial infrastructure,” said Shi Qiu, CEO of the Company. “We are positioning our company to be a key player in the evolving digital financial ecosystem.”

    Concurrently, according to FTSE Russell’s preliminary 2025 annual reconstitution list, the Company is poised to be included in the broad-market Russell 3000® and Russell 2000® Index, representing an upgrade from its prior classification within the Russell Microcap Index. The index reclassification and upgrade could broaden the Company’s exposure to institutional investors, including those managing index-linked and actively managed funds. Furthermore, the Company believes that such inclusion signals to the market that MFH is demonstrating consistent execution capability and growing relevance of its blockchain-based infrastructure strategy within the public markets.

    “Moving from the Russell Microcap to the Russell 2000 shows that investors recognize the value we are creating in blockchain finance,” Qiu added. “Our Bitcoin treasury reserve initiative is the next logical step in this evolution.”

    About Mercurity Fintech Holding Inc.
    Mercurity Fintech Holding Inc. (NASDAQ: MFH) is a fintech group powered by blockchain infrastructure, offering technology and financial services. Through its subsidiaries including Chaince Securities, LLC, MFH aims to bridge traditional finance and digital innovation, offering services spanning digital assets, financial advisory, and capital markets solutions.

    Forward-Looking Statements
    This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

    Contacts:
    International Elite Capital Inc.
    Annabelle Zhang
    Tel: +1(646) 866-7928
    Email: mfhfintech@iecapitalusa.com

    The MIL Network

  • MIL-OSI: Bitcoin Depot Acquires the Assets of Regional Bitcoin ATM Operator Pelicoin, Expanding U.S. Presence

    Source: GlobeNewswire (MIL-OSI)

    ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, announced it has acquired the assets of Pelicoin, LLC, a crypto ATM operator based in New Orleans, Louisiana. The deal will add kiosk locations across Louisiana, Mississippi, Tennessee, Alabama, and Texas, strengthening Bitcoin Depot’s presence in the Gulf South.

    “Pelicoin is a strategic addition to our footprint in a region where we see real opportunity,” said Brandon Mintz, CEO and founder of Bitcoin Depot. “Pelicoin’s locations give us a stronger presence in the Gulf South, and we can immediately apply our scale and experience to operate their machines more efficiently. This acquisition is part of our broader effort to consolidate a fragmented market and extend our leadership in cash-to-crypto access nationwide. As the industry matures, we believe our ability to integrate and optimize smaller networks is a key advantage.”

    Pelicoin’s ATM network will be fully integrated into Bitcoin Depot’s platform in the coming weeks, with all locations transitioning to Bitcoin Depot branding.

    “I’m extremely proud of what we built at Pelicoin,” said Will Haynie, Founder and CEO of Pelicoin. “What started as a small regional effort became a trusted brand throughout the Gulf South. Bitcoin Depot is one of the most respected names in the industry, and their ability to execute on this transaction quickly made them the obvious choice for us. Our network and loyal customers will add value to their growing operation, and those customers will now benefit from the advantages only a large-scale operator can provide, like 24/7 customer support, a strong compliance program, and continued investment in technology and service.”

    For Pelicoin customers, there will be no disruptions. ATMs currently branded as Pelicoin will soon transition to Bitcoin Depot branding, with the same functionality, now backed by 24/7 customer support, a robust compliance team, and the advantages that come from working with an industry leader.

    The financial terms of the transaction were not disclosed. For more information, visit www.bitcoindepot.com.

    About Bitcoin Depot 
    Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 47 states and at thousands of name-brand retail locations in 31 states through its BDCheckout product. The Company has the largest market share in North America with over 8,500 kiosk locations as of June 2025. Learn more at www.bitcoindepot.com

    Cautionary Note Regarding Forward-Looking Statements
    This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, the anticipated effects of the Amendment, and the closing of the Preferred Sale. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,” “plan,” “potential,” “priorities,” “project,” “pursue,” “seek,” “should,” “target,” “when,” “will,” “would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.

    These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.

    We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

    Contacts: 

    Investors  
    Cody Slach
    Gateway Group, Inc.  
    949-574-3860  
    BTM@gateway-grp.com 

    Media  
    Brenlyn Motlagh, Ryan Deloney  
    Gateway Group, Inc. 
    949-574-3860  
    BTM@gateway-grp.com 

    The MIL Network

  • MIL-OSI: Trawick International Expands LATAM Offerings with Corporate IPMI for Businesses in Latin America & the Caribbean

    Source: GlobeNewswire (MIL-OSI)

    MIAMI, June 11, 2025 (GLOBE NEWSWIRE) — Trawick International, a leading provider of international insurance, announced today that it is expanding its innovative Plan VIVA international private medical insurance (IPMI) product line with the launch of VIVA Corporate, a group IPMI plan for businesses across Latin America and the Caribbean.

    Building on the success of Plan VIVA for individuals, VIVA Corporate offers businesses an opportunity to prioritize employee well-being while enhancing their ability to attract and retain top talent. The plan is designed for companies with five or more employees, offering a modular structure that allows organizations to customize coverage according to the specific needs and budget of their workforce.

    VIVA Corporate integrates the same core principles that have made Plan VIVA a preferred choice for international medical coverage: affordability, long-term sustainability, and personalized service. Businesses can select from various coverage options, ensuring their employees receive access to world-class healthcare without unnecessary costs.

    Key features include:

    • Flexible Coverage Options – A modular design that allows businesses to tailor plans to their workforce needs.
    • Premium Stability – Responsible underwriting practices to prevent sudden rate fluctuations.
    • Wellness and Preventive Care – Health programs and early detection screenings to encourage proactive healthcare management.
    • Seamless Digital Experience – A technology-driven platform for enrollment, policy management, and claims processing.
    • Global Access to Top-Tier Medical Facilities – Policyholders receive quality care wherever they are in the world.
    • Financial Security – Coverage reinsured by Lloyd’s of London.

    David Capote, President, Trawick International Latin America, commented, “We’re proud to introduce our new group IPMI plan tailored specifically for businesses across Latin America and the Caribbean. This offering reflects our commitment to providing flexible, high-quality international health coverage that meets the evolving needs of today’s globally mobile workforce. As companies in the region continue to expand and attract top talent, we’re here to ensure their teams are protected, wherever their work takes them.”

    Businesses interested in learning more about how this group IPMI solution can support their employees’ healthcare needs can contact info@trawicklatam.com.

    About Trawick International
    For over 25 years, Trawick International has been a leading provider of international insurance, administration, and assistance services. The company offers a full suite of innovative products and services designed to support today’s globally mobile population. To learn more about Trawick International and the Trawick family of companies, visit trawickholdings.com.

    Media Contact

    Melissa Nicholson
    Director, Corporate Communications
    Trawick International
    Melissa.Nicholson@trawickinternational.com

    The MIL Network

  • MIL-OSI: RTI Connext Receives Industry Recognition as Leading Data Platform for Autonomous Systems

    Source: GlobeNewswire (MIL-OSI)

    SUNNYVALE, Calif., June 11, 2025 (GLOBE NEWSWIRE) — Real-Time Innovations (RTI), the software framework company for physical AI systems, today announced that RTI Connext® has been selected as the winner of the Top Unmanned Systems Data Processing and Analytics Platform award by the Inside Unmanned Systems Innovation Vanguard Awards (IVA) program. This recognition underscores the crucial role Connext plays in providing real-time data connectivity essential for autonomous operations, sensor fusion, and multi-domain coordination in unmanned systems.

    “The challenge of autonomy isn’t just building fast—it’s building right,” said Stan Schneider, CEO of RTI. “Connext provides a proven software framework that helps emerging innovators get to the field faster while enabling established primes to integrate new capabilities. Connext delivers the secure, intelligent foundation needed to scale autonomy across domains.”

    In today’s race to field autonomous systems faster, initiatives like the DoD’s Replicator program are reshaping expectations across the defense landscape. Speed is no longer a goal—it’s the requirement. Connext helps new innovators, including Silicon Valley disruptors, field autonomy concepts quickly. Its proven, standards-based framework eliminates the burden of building infrastructure from scratch. At the same time, established defense primes rely on Connext to move at mission speed, modernizing legacy systems while accelerating the deployment of next-gen capabilities. Connext is already trusted across 2,000+ systems and 500+ programs of record including over 300 autonomous vehicle designs. And yet, Connext also delivers the industry’s most scalable, secure, and future-ready foundation for autonomy.

    Connext excels at tough deployments. It provides the data confidentiality, integrity, and resilience across multiple security domains that autonomous systems need. It can operate reliably in contested environments, where the risk of disruption or compromise is high. Because it can handle these challenges, Connext leads the industry in real-world use, running more than $1 trillion of total deployed systems.

    The pace of unmanned systems development has also raised the bar for real-time data processing and analytics. Meeting this demand requires a robust data infrastructure that can support complex autonomous behaviors across domains—whether in the air, on land, at sea, or in space.

    For more information on RTI in Aerospace & Defense, please visit the RTI website.

    About RTI

    RTI is the software framework company for physical AI systems, with a mission to run a smarter world. RTI Connext® provides the data architecture for over 2,000 designs in Aerospace and Defense, Medtech, Automotive, and Robotics – running in more than $1T of total deployed systems worldwide. Only RTI combines decades of technical expertise with industry-leading software and tools to develop smarter systems, faster. Learn more at www.rti.com.

    The MIL Network

  • MIL-OSI: Sunrun’s Distributed Power Plant Capacity Surpasses 650 Megawatts, Ready to Support Grid Reliability Ahead of Summer Heat and Hurricanes

    Source: GlobeNewswire (MIL-OSI)

    SAN FRANCISCO, June 11, 2025 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), the nation’s leading provider of clean energy as a subscription service, today announced that it is activating more than 130,000 home batteries, representing over two-thirds of Sunrun’s total battery fleet, to support America’s power grid this summer. In its grid service programs, Sunrun has the capability of dispatching 650 megawatts of peak power—enough to power 480,000 homes, or a city the size of Austin, Texas—at critical times every day to help meet America’s skyrocketing demand for electricity.

    “America is entering a period of insatiable, hockey-stick energy demand driven by manufacturing, data centers, and AI,” said Sunrun CEO Mary Powell. “Sunrun’s laser focus on pairing storage with solar puts us in a position to rapidly bring new generating capacity online to stabilize the grid and help lead the nation toward energy independence.”

    Sunrun’s storage-first strategy has placed the company among the top five energy storage operators nationwide, with nearly a gigawatt of total battery capacity installed—the equivalent of a nuclear power plant’s worth of peak power. Sunrun is the largest distributed battery power plant provider and operator in the world. In the first quarter of this year, Sunrun’s storage attachment rate surged to nearly 70% of new solar customers. The company accounts for roughly half of all new home battery installations in the country.

    Sunrun’s dispatchable power plants recently provided hundreds of megawatts of peak power to the grid in several states:

    • Texas: Sunrun dispatched essential energy during unseasonably hot temperatures, providing cost control to all customers of two retail electricity providers.
    • Arizona: Arizona Public Service called on Sunrun for three consecutive days to dispatch essential energy during unseasonably hot temperatures.
    • California: Sunrun’s statewide residential battery power plant dispatched an average of more than 300 megawatts during a recent two-hour peak load window.
    • New York: Orange and Rockland Utilities activated Sunrun’s residential battery power plant—the largest in the state—several times so far this year to relieve grid stress.
    • Puerto Rico: In response to capacity shortfalls from centralized power plants, the island’s utility provider, LUMA, asked Sunrun to dispatch stored solar energy during 26 emergency power events since January.

    As the U.S. prepares for energy demand spikes and rising temperatures, utilities and grid operators are actively planning future battery dispatches to help stabilize the grid and improve reliability. Notably, Orange and Rockland and LUMA have already asked Sunrun to prepare emergency dispatches as both service areas brace for unusually high temperatures.

    In partnership with electric utilities across the country, Sunrun operates 17 dispatchable power plant programs that improve reliability and help prevent blackouts. With the unique ability to deploy utility-scale battery capacity within months, Sunrun delivers critical grid services with unmatched speed. These programs also help utilities avoid or defer transmission and distribution investments, saving money for all families connected to the grid.

    Sunrun’s subscription model is key to its ability to aggregate, manage, and dispatch hundreds of thousands of home batteries to improve grid reliability. The 48E investment tax credit enables the construction of this grid infrastructure to quickly address America’s looming electricity supply crisis.

    About Sunrun
    Sunrun Inc. (Nasdaq: RUN) revolutionized the solar industry in 2007 by removing financial barriers and democratizing access to locally-generated, renewable energy. Today, Sunrun is the nation’s leading provider of clean energy as a subscription service, offering residential solar and storage with no upfront costs. Sunrun’s innovative products and solutions can connect homes to the cleanest energy on earth, providing them with energy security, predictability, and peace of mind. Sunrun also manages energy services that benefit communities, utilities, and the electric grid while enhancing customer value. Discover more at www.sunrun.com

    Media Contact
    Wyatt Semanek
    Director, Corporate Communications
    press@sunrun.com

    Investor & Analyst Contact
    Patrick Jobin
    SVP, Deputy CFO & Investor Relations Officer
    investors@sunrun.com

    The MIL Network

  • MIL-OSI: BigCommerce Earns 2025 Top Rated Award from TrustRadius

    Source: GlobeNewswire (MIL-OSI)

    AUSTIN, Texas, June 11, 2025 (GLOBE NEWSWIRE) — BigCommerce (Nasdaq: BIGC), a leading provider of open, composable commerce solutions for B2C and B2B brands, retailers, manufacturers and distributors, today announced that TrustRadius has recognized BigCommerce with a 2025 Top Rated Award.

    With a TRScore of 7.8 out of 10 and over 450 reviews, BigCommerce is recognized by their customer reviews as a top player in the ecommerce category.

    “This recognition is based entirely on our customers’ positive sentiment and is especially fulfilling because it reflects the value they receive from our platform as well as our customer success services,” said Ryan Means, senior vice president of global services at BigCommerce. “Winning this TrustRadius award validates that our customers are successful with our platform and it is helping them optimize revenue and grow their businesses.”

    “BigCommerce earning a TrustRadius Top Rated award showcases its impact in empowering merchants to scale without limits,” said Allyson Havener, chief marketing officer at TrustRadius. “Their customers consistently praise BigCommerce for its flexibility, robust feature set, and ease of use—making it a trusted platform for businesses looking to grow and compete in an ever-evolving eCommerce landscape.”

    Since 2016, the TrustRadius Top Rated Awards have become the B2B’s industry standard for unbiased recognition of excellent technology products. Based entirely on customer feedback, they have never been influenced by analyst opinion or status as a TrustRadius customer. Here is a detailed criteria breakdown of the methodology and scoring that TrustRadius uses to determine Top Rated winners.

    Hear from verified users on how much they value BigCommerce:

    “Big commerce certainly helped us increase our web traffic through its integrated SEO,” wrote one review. “SEO is super important for web visibility/where your page ranks on search engines. The integrated SEO along with the integrated search analytics really helps us target/cater to what our customers or potential customers are searching for.”

    “BigCommerce had a much stronger B2B integration and platform in general than Shopify,” said another reviewer. “Netsuite was too expensive at the time to consider it.”

    BigCommerce is proud to create products that inspire such gracious feedback in our user community. Looking to share your own feedback? Please leave a review here.

    About BigCommerce
    BigCommerce (Nasdaq: BIGC) is a leading open SaaS and composable ecommerce platform that empowers brands, retailers, manufacturers and distributors of all sizes to build, innovate and grow their businesses online. BigCommerce provides its customers sophisticated professional-grade functionality, customization and performance with simplicity and ease-of-use. Tens of thousands of B2C and B2B companies across 150 countries and numerous industries rely on BigCommerce, including Coldwater Creek, Harvey Nichols, King Arthur Baking Co., MKM Building Supplies, United Aqua Group and Uplift Desk. For more information, please visit www.bigcommerce.com or follow us on X and LinkedIn.

    BigCommerce® is a registered trademark of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owners.

    About TrustRadius:
    TrustRadius is a buyer intelligence platform for business technology. We enable buyers to make confident decisions, through comprehensive product information, in-depth customer insights, and peer conversations. We help technology brands capture and activate the authentic voice of customers to improve their products, build confidence with prospects, and engage in-market buyers to improve ROI. Founded by successful entrepreneurs and headquartered in the technology hub of Austin, Texas, TrustRadius is backed by Mayfield Fund, LiveOak Venture Partners, and Next Coast Ventures.

    Media Contact:
    Brad Hem
    pr@bigcommerce.com

    The MIL Network

  • MIL-OSI: OSS’s BRESSNER Receives the 2024 EMEA Growth Partner of the Year Award from Digi International

    Source: GlobeNewswire (MIL-OSI)

    ESCONDIDO, Calif., June 11, 2025 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS) today announced that its subsidiary, BRESSNER Technology GmbH, a leading specialized high-performance computing supplier in Europe, has been named Digi International’s 2024 EMEA Growth Partner of the Year.

    Digi International’s prestigious Global Channel Awards are given annually to Digi’s most impactful worldwide channel partners, celebrating their leadership, innovation, customer-first mindset, and outstanding contributions to the expansion of connected technologies.

    “Digi is a long-standing partner, and we are honored to be named their 2024 EMEA Growth Partner of the Year,” said Martin Stiborski, Managing Director of BRESSNER. “This award reflects our commitment to providing state-of-the-art hardware solutions for demanding applications.”

    “Our channel partners are at the heart of Digi’s global success,” said Ron Konezny, President and CEO of Digi International. “Each award recipient has demonstrated unmatched dedication to advancing IoT and infrastructure management, while delivering exceptional value to customers in every region we serve. Their commitment and results speak volumes — and together, we are empowering digital transformation across industries and geographies.”

    To learn more and view this year’s additional winners, visit:
    https://www.digi.com/company/press-releases/2025/digi-celebrates-2024-global-channel-awards   

    About BRESSNER Technology GmbH
    As a system integrator, manufacturer, value-added distributor, and system house for industrial hardware solutions, components, accessories, and built-to-order solutions, BRESSNER offers an extensive portfolio for various applications in the industrial environment. Tailored solutions for machine automation, logistics & transport, and production are part of the company’s range of services, as well as comprehensive support for topics such as AI applications, machine/deep learning, networks, intelligent retail, communication, and security. The company’s headquarters is located in Germany, with its parent company, One Stop Systems, based in the USA.

    About One Stop Systems
    One Stop Systems, Inc. (Nasdaq: OSS) is a leader in AI enabled solutions for the demanding ‘edge’. OSS designs and manufactures Enterprise Class compute and storage products that enable rugged AI, sensor fusion and autonomous capabilities without compromise. These hardware and software platforms bring the latest data center performance to harsh and challenging applications, whether they are on land, sea or in the air.

    OSS products include ruggedized servers, compute accelerators, flash storage arrays, and storage acceleration software. These specialized compact products are used across multiple industries and applications, including autonomous trucking and farming, as well as aircraft, drones, ships and vehicles within the defense industry.

    OSS solutions address the entire AI workflow, from high-speed data acquisition to deep learning, training and large-scale inference, and have delivered many industry firsts for industrial OEM and government customers.

    As the fastest growing segment of the multi-billion-dollar edge computing market, AI enabled solutions require-and OSS delivers-the highest level of performance in the most challenging environments without compromise.

    OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com. You can also follow OSS on X, YouTube, and LinkedIn.

    Forward-Looking Statements
    One Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by One Stop Systems or its partners that any of our plans or expectations will be achieved, including but not limited to the potential and/or the results participating in the ROTH Conference, any results relating to one-on-one meetings with management, and the expansion of the Company’s offerings and/or relationship with commercial customers and/or investors. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business, including risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our latest Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Media Contacts:
    Robert Kalebaugh
    One Stop Systems, Inc.
    Tel (858) 518-6154
    Email contact

    Investor Relations:
    Andrew Berger
    Managing Director
    SM Berger & Company, Inc.
    Tel (216) 464-6400
    Email contact

    The MIL Network

  • MIL-OSI: Form 8.3 – [MARLOWE PLC – 10 06 2025] – (CGWL)

    Source: GlobeNewswire (MIL-OSI)

    FORM 8.3

    PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
    A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
    Rule 8.3 of the Takeover Code (the “Code”)

    1.        KEY INFORMATION

    (a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)
    (b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
            The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
    N/A
    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
            Use a separate form for each offeror/offeree
    MARLOWE PLC
    (d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
    (e)   Date position held/dealing undertaken:
            For an opening position disclosure, state the latest practicable date prior to the disclosure
    10 JUNE 2025
    (f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
            If it is a cash offer or possible cash offer, state “N/A”
    NO

    2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

    If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

    (a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

    Class of relevant security: 50p ORDINARY
      Interests Short positions
    Number % Number %
    (1)   Relevant securities owned and/or controlled: 3,112,147 3.9634    
    (2)   Cash-settled derivatives:        
    (3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
    TOTAL: 3,112,147 3.9634    

    All interests and all short positions should be disclosed.

    Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

    (b)      Rights to subscribe for new securities (including directors’ and other employee options)

    Class of relevant security in relation to which subscription right exists:  
    Details, including nature of the rights concerned and relevant percentages:  

    3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

    Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

    The currency of all prices and other monetary amounts should be stated.

    (a)        Purchases and sales

    Class of relevant security Purchase/sale Number of securities Price per unit
    50p ORDINARY SALE 2,065 437.65p
    50p ORDINARY SALE 710 440p
    50p ORDINARY SALE 1,480 440.35p

    (b)        Cash-settled derivative transactions

    Class of relevant security Product description
    e.g. CFD
    Nature of dealing
    e.g. opening/closing a long/short position, increasing/reducing a long/short position
    Number of reference securities Price per unit
    NONE        

    (c)        Stock-settled derivative transactions (including options)

    (i)        Writing, selling, purchasing or varying

    Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
    e.g. American, European etc.
    Expiry date Option money paid/ received per unit
    NONE              

    (ii)        Exercise

    Class of relevant security Product description
    e.g. call option
    Exercising/ exercised against Number of securities Exercise price per unit

    (d)        Other dealings (including subscribing for new securities)

    Class of relevant security Nature of dealing
    e.g. subscription, conversion
    Details Price per unit (if applicable)
    NONE      

    4.        OTHER INFORMATION

    (a)        Indemnity and other dealing arrangements

    Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
    Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

    NONE

    (b)        Agreements, arrangements or understandings relating to options or derivatives

    Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
    (i)   the voting rights of any relevant securities under any option; or
    (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
    If there are no such agreements, arrangements or understandings, state “none”

    NONE

    (c)        Attachments

    Is a Supplemental Form 8 (Open Positions) attached? NO
    Date of disclosure: 11 JUNE 2025
    Contact name: MARK ELLIOTT
    Telephone number: 01253 376539

    Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

    The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

    The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

    The MIL Network

  • MIL-OSI: EBC Financial Group Launches over a 100 U.S. ETF CFDs, Strengthening Diversification for Global Clients

    Source: GlobeNewswire (MIL-OSI)

    LONDON, June 11, 2025 (GLOBE NEWSWIRE) — EBC Financial Group (EBC) has announced the launch of over 100 new U.S.-listed Exchange-Traded Fund (ETF) CFDs, expanding its multi-asset product suite and offering global client’s deeper access to diversified, thematic trading opportunities. The rollout highlights EBC’s ongoing commitment to delivering institutional-grade tools across asset classes, underpinned by flexibility, transparency, and efficiency.

    The new offering includes ETFs listed on the NYSE and NASDAQ, issued by leading asset managers such as Vanguard, iShares (BlackRock), and State Street Global Advisors. Thematic coverage spans a wide range of global macro and sectoral narratives.

    “This expansion reflects our vision to bridge intelligent product design with market relevance,” said David Barrett, CEO of EBC Financial Group (UK) Ltd. “The new products are a natural evolution for traders seeking targeted exposure with greater strategic flexibility. At EBC, we’re building an ecosystem that empowers both precision and performance.”

    Thematic Access Meets Tactical Flexibility

    The additional ETF-linked instruments cover a variety of market exposures, including geographic allocations like the iShares MSCI Brazil ETF; fixed income-focused strategies such as the iShares iBoxx $ High Yield Corporate Bond Fund; and sector- or commodity-based indices including the United States Oil Fund LP and the Vanguard Health Care ETF. Other themes include dividend-related baskets, mid-cap equities, and style-based index tracking.

    These developments reflect wider industry interest in instruments that mirror trends in asset allocation without direct ownership of the underlying securities. Across many markets, sector-tilted and style-based index products are gaining relevance as participants seek flexible ways to align with global narratives.

    Historically, ETFs tracking specific economic cycles—such as commodity recoveries or emerging market rebounds—have demonstrated performance differentiation. The iShares MSCI Brazil ETF, for example, notably outperformed the S&P 500 during the post-pandemic recovery period in 2021, highlighting how thematic instruments can diverge from broad indices depending on market cycles.

    These additions serve as both stand-alone trade ideas and complementary instruments alongside EBC’s existing product lineup, enabling advanced portfolio structuring and thematic trading.

    Smarter Exposure: Leverage, Shorting, and Cost Efficiency in One Product

    Compared to direct ETF investments, it presents several key advantages as traders benefit from a simplified cost structure, with no traditional fund management fees or broker commissions. The flexibility to take both long and short positions allows for strategic trading regardless of market direction, while the use of leverage enhances capital efficiency and return potential. These trades are executed in real time via EBC’s recognised platforms, providing seamless access to market opportunities.

    During key market cycles, for example the post-pandemic V-shaped recovery of 2021—certain thematic ETFs, like the iShares MSCI Brazil ETF, significantly outperformed broader indices such as the S&P 500. Our portfolio enables traders to participate in similar trends, adapting quickly to shifting market dynamics with precision and speed.

    Getting Started

    These products can be accessed by registering on www.ebc.com to begin simulated or live trading.

    About EBC Financial Group  
    Founded in London’s esteemed financial district, EBC Financial Group (EBC) is a global brand known for its expertise in financial brokerage and asset management. Through its regulated entities operating across major financial jurisdictions—including the UK, Australia, the Cayman Islands, Mauritius, and others—EBC enables retail, professional, and institutional investors to access a wide range of global markets and trading opportunities, including currencies, commodities, shares, and indices.

    Recognised with multiple awards, EBC is committed to upholding ethical standards and is licensed and regulated within the respective jurisdictions. EBC Financial Group (UK) Limited is regulated by the UK’s Financial Conduct Authority (FCA); EBC Financial Group (Cayman) Limited is regulated by the Cayman Islands Monetary Authority (CIMA); EBC Financial Group (Australia) Pty Ltd, and EBC Asset Management Pty Ltd are regulated by Australia’s Securities and Investments Commission (ASIC);  EBC Financial (MU) Ltd is authorised and regulated by the Financial Services Commission Mauritius (FSC).  

    At the core of EBC are a team of industry veterans with over 40 years of experience in major financial institutions. Having navigated key economic cycles from the Plaza Accord and 2015 Swiss franc crisis to the market upheavals of the COVID-19 pandemic. We foster a culture where integrity, respect, and client asset security are paramount, ensuring that every investor relationship is handled with the utmost seriousness it deserves.   

    As the Official Foreign Exchange Partner of FC Barcelona, EBC provides specialised services across Asia, LATAM, the Middle East, Africa, and Oceania. Through its partnership with United to Beat Malaria, the company contributes to global health initiatives. EBC also supports the ‘What Economists Really Do’ public engagement series by Oxford University’s Department of Economics, helping to demystify economics and its application to major societal challenges, fostering greater public understanding and dialogue.  

    https://www.ebc.com/ 

    Media Contact:
    Savitha Ravindran
    Global Public Relations Manager
    savitha.ravindran@ebc.com

    Michelle Siow
    Brand & Communications Director
    michelle.siow@ebc.com

    The MIL Network

  • MIL-OSI: NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery

    Source: GlobeNewswire (MIL-OSI)

    PARIS, June 11, 2025 (GLOBE NEWSWIRE) — NVIDIA GTC Paris at VivaTech NVIDIA today announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. The work supports Novo Nordisk’s agreement with DCAI to use the Gefion sovereign AI supercomputer.

    The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development and to apply advanced simulation and physical AI technologies.

    “AI is essential for every industry, and there’s no other field that will benefit more from acceleration than drug discovery,” said Rory Kelleher, senior director of business development for life sciences at NVIDIA. “Working with Novo Nordisk, we’re advancing critical R&D applications with fundamental tools that can harness the full potential of generative and agentic AI to improve pharmaceutical development.”

    Novo Nordisk Taps Advanced AI to Accelerate Innovation
    DCAI’s Gefion supercomputer, powered by NVIDIA DGX SuperPOD™, provides Novo Nordisk an AI factory for running drug discovery and agentic AI workloads. Novo Nordisk will use NVIDIA BioNeMo™ for generative AI-powered drug discovery, NVIDIA NIM™ and NVIDIA NeMo™ microservices for building customized agentic workflows, and the NVIDIA Omniverse™ platform to create physically accurate simulation environments for developing physical AI applications.

    Novo Nordisk researchers will focus on several AI research programs, including using single-cell models to predict cellular responses to drug candidates and structures, as well as designing models to build molecules with drug-like properties. The companies will also collaborate on tapping Novo Nordisk’s vast global scientific literature to build biomedical large language models, enabling researchers to uncover correlations between genes, proteins and diseases.

    “By coupling NVIDIA’s accelerated computing platform and expertise with Novo’s deep expertise in life sciences research and development, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently,” said Mishal Patel, senior vice president, AI and digital innovation at Novo Nordisk. “Gefion will allow us to run experiments at an unprecedented scale.”

    Advancing Denmark’s Healthcare Ecosystem
    DCAI owns and operates Gefion, Denmark’s flagship AI supercomputer. DCAI is helping lower the barrier for accessing advanced computing capabilities and enabling companies in Denmark to pursue research and development across healthcare and drug discovery.

    “With Gefion’s computational power, we can tackle the toughest R&D challenges, with the ultimate goal of unlocking new possibilities for pharmaceutical research and development,” said Nadia Carlsten, CEO of DCAI. “By combining Gefion’s capabilities with NVIDIA’s expertise, our customers can accelerate innovation even further.”

    Gefion has already been used by multiple customers to advance healthcare and drug discovery.

    Teton, a Danish startup and member of the NVIDIA Inception program for cutting-edge startups, is tapping into Gefion to accelerate the development of its AI care companion for hospitals, using cameras and sensors installed in patient rooms to create real-time 3D digital twins. This allows nurses to monitor patients remotely and receive alerts about potential health issues. Teton’s technology aims to reduce workload burden on nurses — freeing them up for higher-value tasks — and improve patient care, with early trials showing up to a 25% reduction in nightshift duties.

    Last month, DCAI announced that one of the first pharma companies to use Gefion will tap the supercomputer to accelerate drug discovery and development in neurological and psychiatric disorders. Another venture-backed company is using Gefion to accelerate the development of oral alternatives to widely used biologics and to target proteins that are currently difficult or impossible to drug with available compounds.

    Gefion will also be used as part of an effort by Danish health organizations to unite previously siloed health data into a single national analysis platform, which will provide researchers with secure access to interconnected health data. Along with supercomputing resources, this will make it easier to analyze large datasets, identify disease patterns earlier and develop more personalized treatments.

    Watch the NVIDIA GTC Paris keynote from NVIDIA founder and CEO Jensen Huang at VivaTech, and explore GTC Paris sessions.

    About NVIDIA
    NVIDIA (NASDAQ: NVDA) is the world leader in accelerated computing.

    For further information, contact:
    Janette Ciborowski
    Enterprise Communications
    NVIDIA Corporation
    +1-734-330-8817
    jciborowski@nvidia.com

    Certain statements in this press release including, but not limited to, statements as to: working with Novo Nordisk, NVIDIA advancing critical R&D applications with fundamental tools that can harness the full potential of generative and agentic AI to improve pharmaceutical development; the benefits, impact, performance, and availability of NVIDIA’s products, services, and technologies; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing product and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

    © 2025 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, NVIDIA BioNeMo, NVIDIA DGX SuperPOD, NVIDIA NeMo, NVIDIA NIM and NVIDIA Omniverse are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/92c0c3db-28ea-43c7-b0d5-9ac3b350edaf

    The MIL Network

  • MIL-OSI: YieldMax® ETFs Announces Distributions on SNOY, ULTY, TSMY, CRSH, YMAX and Others

    Source: GlobeNewswire (MIL-OSI)

    CHICAGO and MILWAUKEE and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) — YieldMax® today announced distributions for the YieldMax®Weekly Payers and Group A ETFs listed in the table below.

    ETF Ticker1 ETF Name Distribution Frequency Distribution per Share Distribution Rate2,4 30-Day
    SEC Yield3
    ROC5 Ex-Date & Record Date Payment Date
    CHPY YieldMax® Semiconductor Portfolio Option Income ETF Weekly $0.4031 39.14% 0.38% 100.00% 6/12/25 6/13/25
    GPTY YieldMax® AI & Tech Portfolio Option Income ETF Weekly $0.3070 34.41% 0.00% 100.00% 6/12/25 6/13/25
    LFGY YieldMax® Crypto Industry & Tech Portfolio Option Income ETF Weekly $0.4724 60.93% 0.00% 100.00% 6/12/25 6/13/25
    QDTY YieldMax® Nasdaq 100 0DTE Covered Call ETF Weekly $0.2572 31.02% 0.00% 100.00% 6/12/25 6/13/25
    RDTY YieldMax® R2000 0DTE Covered Call ETF Weekly $0.3038 34.15% 0.89% 96.74% 6/12/25 6/13/25
    SDTY YieldMax® S&P 500 0DTE Covered Call ETF Weekly $0.2258 26.59% 0.00% 100.00% 6/12/25 6/13/25
    ULTY YieldMax® Ultra Option Income Strategy ETF Weekly $0.0950 79.31% 0.00% 100.00% 6/12/25 6/13/25
    YMAG YieldMax® Magnificent 7 Fund of Option Income ETFs Weekly $0.1709 57.55% 66.50% 94.20% 6/12/25 6/13/25
    YMAX YieldMax® Universe Fund of Option Income ETFs Weekly $0.1803 68.10% 88.53% 96.28% 6/12/25 6/13/25
    BRKC* YieldMax® BRK.B Option Income Strategy ETF Every 4 weeks
    CRSH YieldMax® Short TSLA Option Income Strategy ETF Every 4 weeks $0.2534 68.77% 3.08% 95.13% 6/12/25 6/13/25
    FEAT YieldMax® Dorsey Wright Featured 5 Income ETF Every 4 weeks $1.1206 39.67% 52.99% 0.00% 6/12/25 6/13/25
    FIVY YieldMax® Dorsey Wright Hybrid 5 Income ETF Every 4 weeks $1.0634 35.12% 35.26% 0.00% 6/12/25 6/13/25
    GOOY YieldMax® GOOGL Option Income Strategy ETF Every 4 weeks $0.3978 40.78% 3.29% 87.70% 6/12/25 6/13/25
    OARK YieldMax® Innovation Option Income Strategy ETF Every 4 weeks $0.3947 60.87% 2.88% 95.83% 6/12/25 6/13/25
    SNOY YieldMax® SNOW Option Income Strategy ETF Every 4 weeks $1.2757 95.23% 2.27% 97.79% 6/12/25 6/13/25
    TSLY YieldMax® TSLA Option Income Strategy ETF Every 4 weeks $0.4028 60.47% 2.76% 95.33% 6/12/25 6/13/25
    TSMY YieldMax® TSM Option Income Strategy ETF Every 4 weeks $0.8958 70.48% 2.87% 96.58% 6/12/25 6/13/25
    XOMO YieldMax® XOM Option Income Strategy ETF Every 4 weeks $0.2498 25.49% 3.62% 80.62% 6/12/25 6/13/25
    YBIT YieldMax® Bitcoin Option Income Strategy ETF Every 4 weeks $0.3314 39.49% 1.54% 97.41% 6/12/25 6/13/25
    Weekly Payers & Group B ETFs scheduled for next week: CHPY GPTY LFGY QDTY RDTY SDTY UTLY YMAG YMAX BABO DIPS FBY GDXY JPMO MARO MRNY NVDY PLTY
     

    Standardized Performance and Fund details can be obtained by clicking the ETF Ticker in the table above or by visiting us at www.yieldmaxetfs.com

    Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted above. Performance current to the most recent month-end can be obtained by calling (833) 378-0717.

    Note: DIPS, FIAT, CRSH, YQQQ and WNTR are hereinafter referred to as the “Short ETFs.”

    Distributions are not guaranteed. The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs. In particular, future distributions on any ETF may differ significantly from its Distribution Rate or 30-Day SEC Yield. You are not guaranteed a distribution under the ETFs. Distributions for the ETFs (if any) are variable and may vary significantly from period to period and may be zero. Accordingly, the Distribution Rate and 30-Day SEC Yield will change over time, and such change may be significant.

    Investors in the Funds will not have rights to receive dividends or other distributions with respect to the underlying reference asset(s).

    *The inception date for BRKC is June 4, 2025.

    1. All YieldMax®ETFs shown in the table above (except YMAX, YMAG, FEAT, FIVY and ULTY) have a gross expense ratio of 0.99%. YMAX, FEAT have a Management Fee of 0.29% and Acquired Fund Fees and Expenses of 0.99% for a gross expense ratio of 1.28%. YMAG has a management fee of 0.29% and Acquired Fund Fees and Expenses of 0.83% for a gross expense ratio of 1.12%. FIVY has a Management Fee of 0.29% and Acquired Fund Fees and Expenses of 0.59% for a gross expense ratio of 0.88%. “Acquired Fund Fees and Expenses” are on fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other YieldMax®ETFs. ULTY has a gross expense ratio of 1.40%, and a net expense ratio after the fee waiver of 1.30%. The Advisor has agreed to a fee waiver of 0.10% through at least February 28, 2026.
    2. The Distribution Rate shown is as of close on June 10, 2025. The Distribution Rate is the annual distribution rate an investor would receive if the most recent distribution, which includes option income, remained the same going forward. The Distribution Rate is calculated by annualizing an ETF’s Distribution per Share and dividing such annualized amount by the ETF’s most recent NAV. The Distribution Rate represents a single distribution from the ETF and does not represent its total return. Distributions may also include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease an ETF’s NAV and trading price over time. As a result, an investor may suffer significant losses to their investment. These Distribution Rates may be caused by unusually favorable market conditions and may not be sustainable. Such conditions may not continue to exist and there should be no expectation that this performance may be repeated in the future.
    3. The 30-Day SEC Yield represents net investment income, which excludes option income, earned by such ETF over the 30-Day period ended May 31, 2025, expressed as an annual percentage rate based on such ETF’s share price at the end of the 30-Day period.
    4. Each ETF’s strategy (except those of the Short ETFs) will cap potential gains if its reference asset’s shares increase in value, yet subjects an investor to all potential losses if the reference asset’s shares decrease in value. Such potential losses may not be offset by income received by the ETF. Each Short ETF’s strategy will cap potential gains if its reference asset decreases in value, yet subjects an investor to all potential losses if the reference asset increases in value. Such potential losses may not be offset by income received by the ETF.
    5. ROC refers to Return of Capital. The ROC percentage indicates how much the distribution reflects an investor’s initial investment. The figures shown for each Fund in the table above are estimates and may later be determined to be taxable net investment income, short-term gains, long-term gains (to the extent permitted by law), or return of capital. Actual amounts and sources for tax reporting will depend upon the Fund’s investment activities during the remainder of the fiscal year and may be subject to changes based on tax regulations. Your broker will send you a Form 1099-DIV for the calendar year to tell you how to report these distributions for federal income tax purposes

    Each Fund has a limited operating history and while each Fund’s objective is to provide current income, there is no guarantee the Fund will make a distribution. Distributions are likely to vary greatly in amount.

    Important Information

    This material must be preceded or accompanied by the prospectus. For all prospectuses, click here.

    Contact Vince DiLullo at vdilullo@tidalfg.com for more information.

    Tidal Financial Group is the adviser for all YieldMax® ETFs.

    THE FUND, TRUST, AND ADVISER ARE NOT AFFILIATED WITH ANY UNDERLYING REFERENCE ASSET.

    Risk Disclosures (applicable to all YieldMax ETFs referenced above, except the Short ETFs)

    YMAX, YMAG, FEAT and FIVY generally invest in other YieldMax® ETFs. As such, these Funds are subject to the risks listed in this section, which apply to all the YieldMax® ETFs they may hold from time to time.

    Investing involves risk. Principal loss is possible.

    Referenced Index Risk. The Fund invests in options contracts that are based on the value of the Index (or the Index ETFs). This subjects the Fund to certain of the same risks as if it owned shares of companies that comprised the Index or an ETF that tracks the Index, even though it does not.

    Indirect Investment Risk. The Index is not affiliated with the Trust, the Fund, the Adviser, or their respective affiliates and is not involved with this offering in any way. Investors in the Fund will not have the right to receive dividends or other distributions or any other rights with respect to the companies that comprise the Index but will be subject to declines in the performance of the Index.

    Russell 2000 Index Risks. The Index, which consists of small-cap U.S. companies, is particularly susceptible to economic changes, as these firms often have less financial resilience than larger companies. Market volatility can disproportionately affect these smaller businesses, leading to significant price swings. Additionally, these companies are often more exposed to specific industry risks and have less diverse revenue streams. They can also be more vulnerable to changes in domestic regulatory or policy environments.

    Call Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund’s call writing strategy will impact the extent that the Fund participates in the positive price returns of the underlying reference asset and, in turn, the Fund’s returns, both during the term of the sold call options and over longer periods.

    Counterparty Risk. The Fund is subject to counterparty risk by virtue of its investments in options contracts. Transactions in some types of derivatives, including options, are required to be centrally cleared (“cleared derivatives”). In a transaction involving cleared derivatives, the Fund’s counterparty is a clearing house rather than a bank or broker. Since the Fund is not a member of clearing houses and only members of a clearing house (“clearing members”) can participate directly in the clearing house, the Fund will hold cleared derivatives through accounts at clearing members.

    Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. The Fund’s investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, imperfect correlation with underlying investments or the Fund’s other portfolio holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions.

    Options Contracts. The use of options contracts involves investment strategies and risks different from those associated with ordinary portfolio securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying instrument, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events.

    Distribution Risk. As part of the Fund’s investment objective, the Fund seeks to provide current income. There is no assurance that the Fund will make a distribution in any given period. If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

    High Portfolio Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings. A high portfolio turnover rate increases transaction costs, which may increase the Fund’s expenses.

    Liquidity Risk. Some securities held by the Fund, including options contracts, may be difficult to sell or be illiquid, particularly during times of market turmoil.

    Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund.

    New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

    Price Participation Risk. The Fund employs an investment strategy that includes the sale of call option contracts, which limits the degree to which the Fund will participate in increases in value experienced by the underlying reference asset over the Call Period.

    Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally. The value of the Fund, which focuses on an individual security (ARKK, TSLA, AAPL, NVDA, AMZN, META, GOOGL, NFLX, COIN, MSFT, DIS, XOM, JPM, AMD, PYPL, SQ, MRNA, AI, MSTR, Bitcoin ETP, GDX®, SNOW, ABNB, BABA, TSM, SMCI, PLTR, MARA, CVNA, HOOD, BRK.B), may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole.

    Inflation Risk. Inflation risk is the risk that the value of assets or income from investments will be less in the future as inflation decreases the value of money. As inflation increases, the present value of the Fund’s assets and distributions, if any, may decline.

    Indirect Investment Risk. The Index is not affiliated with the Trust, the Fund, the Adviser, or their respective affiliates and is not involved with this offering in any way.

    Risk Disclosures (applicable only to GPTY)

    Artificial Intelligence Risk. Issuers engaged in artificial intelligence typically have high research and capital expenditures and, as a result, their profitability can vary widely, if they are profitable at all. The space in which they are engaged is highly competitive and issuers’ products and services may become obsolete very quickly. These companies are heavily dependent on intellectual property rights and may be adversely affected by loss or impairment of those rights. The issuers are also subject to legal, regulatory, and political changes that may have a large impact on their profitability. A failure in an issuer’s product or even questions about the safety of the product could be devastating to the issuer, especially if it is the marquee product of the issuer. It can be difficult to accurately capture what qualifies as an artificial intelligence company.

    Technology Sector Risk. The Fund will invest substantially in companies in the information technology sector, and therefore the performance of the Fund could be negatively impacted by events affecting this sector. Market or economic factors impacting technology companies and companies that rely heavily on technological advances could have a significant effect on the value of the Fund’s investments. The value of stocks of information technology companies and companies that rely heavily on technology is particularly vulnerable to rapid changes in technology product cycles, rapid product obsolescence, government regulation and competition, both domestically and internationally, including competition from foreign competitors with lower production costs. Stocks of information technology companies and companies that rely heavily on technology, especially those of smaller, less-seasoned companies, tend to be more volatile than the overall market. Information technology companies are heavily dependent on patent and intellectual property rights, the loss or impairment of which may adversely affect profitability.

    Risk Disclosure (applicable only to MARO)

    Digital Assets Risk: The Fund does not invest directly in Bitcoin or any other digital assets. The Fund does not invest directly in derivatives that track the performance of Bitcoin or any other digital assets. The Fund does not invest in or seek direct exposure to the current “spot” or cash price of Bitcoin. Investors seeking direct exposure to the price of Bitcoin should consider an investment other than the Fund. Digital assets like Bitcoin, designed as mediums of exchange, are still an emerging asset class. They operate independently of any central authority or government backing and are subject to regulatory changes and extreme price volatility.

    Risk Disclosures (applicable only to BABO and TSMY)

    Currency Risk: Indirect exposure to foreign currencies subjects the Fund to the risk that currencies will decline in value relative to the U.S. dollar. Currency rates in foreign countries may fluctuate significantly over short periods of time for a number of reasons, including changes in interest rates and the imposition of currency controls or other political developments in the U.S. or abroad.

    Depositary Receipts Risk: The securities underlying BABO and TSMY are American Depositary Receipts (“ADRs”). Investment in ADRs may be less liquid than the underlying shares in their primary trading market.

    Foreign Market and Trading Risk: The trading markets for many foreign securities are not as active as U.S. markets and may have less governmental regulation and oversight.

    Foreign Securities Risk: Investments in securities of non-U.S. issuers involve certain risks that may not be present with investments in securities of U.S. issuers, such as risk of loss due to foreign currency fluctuations or to political or economic instability, as well as varying regulatory requirements applicable to investments in non-U.S. issuers. There may be less information publicly available about a non-U.S. issuer than a U.S. issuer. Non-U.S. issuers may also be subject to different regulatory, accounting, auditing, financial reporting, and investor protection standards than U.S. issuers.

    Risk Disclosures (applicable only to GDXY)

    Risk of Investing in Foreign Securities. The Fund is exposed indirectly to the securities of foreign issuers selected by GDX®’s investment adviser, which subjects the Fund to the risks associated with such companies. Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities.

    Risk of Investing in Gold and Silver Mining Companies. The Fund is exposed indirectly to gold and silver mining companies selected by GDX®’s investment adviser, which subjects the Fund to the risks associated with such companies.

    The Fund invests in options contracts based on the value of the VanEck Gold Miners ETF (GDX®), which subjects the Fund to some of the same risks as if it owned GDX®, as well as the risks associated with Canadian, Australian and Emerging Market Issuers, and Small-and Medium-Capitalization companies.

    Risk Disclosures (applicable only to YBIT)

    YBIT does not invest directly in Bitcoin or any other digital assets. YBIT does not invest directly in derivatives that track the performance of Bitcoin or any other digital assets. YBIT does not invest in or seek direct exposure to the current “spot” or cash price of Bitcoin. Investors seeking direct exposure to the price of Bitcoin should consider an investment other than YBIT.

    Bitcoin Investment Risk: The Fund’s indirect investment in Bitcoin, through holdings in one or more Underlying ETPs, exposes it to the unique risks of this emerging innovation. Bitcoin’s price is highly volatile, and its market is influenced by the changing Bitcoin network, fluctuating acceptance levels, and unpredictable usage trends.

    Digital Assets Risk: Digital assets like Bitcoin, designed as mediums of exchange, are still an emerging asset class. They operate independently of any central authority or government backing and are subject to regulatory changes and extreme price volatility. Potentially No 1940 Act Protections. As of the date of this Prospectus, there is only a single eligible Underlying ETP, and it is an investment company subject to the 1940 Act.

    Bitcoin ETP Risk: The Fund invests in options contracts that are based on the value of the Bitcoin ETP. This subjects the Fund to certain of the same risks as if it owned shares of the Bitcoin ETP, even though it does not. Bitcoin ETPs are subject, but not limited, to significant risk and heightened volatility. An investor in a Bitcoin ETP may lose their entire investment. Bitcoin ETPs are not suitable for all investors. In addition, not all Bitcoin ETPs are registered under the Investment Company Act of 1940. Those Bitcoin ETPs that are not registered under such statute are therefore not subject to the same regulations as exchange traded products that are so registered.

    Risk Disclosures (applicable only to the Short ETFs)

    Investing involves risk. Principal loss is possible.

    Price Appreciation Risk. As part of the Fund’s synthetic covered put strategy, the Fund purchases and sells call and put option contracts that are based on the value of the underlying reference asset. This strategy subjects the Fund to certain of the same risks as if it shorted the underlying reference asset, even though it does not. By virtue of the Fund’s indirect inverse exposure to changes in the value of the underlying reference asset, the Fund is subject to the risk that the value of the underlying reference asset increases. If the value of the underlying reference asset increases, the Fund will likely lose value and, as a result, the Fund may suffer significant losses.

    Put Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund’s put writing (selling) strategy will impact the extent that the Fund participates in decreases in the value of the underlying reference asset and, in turn, the Fund’s returns, both during the term of the sold put options and over longer periods.

    Purchased OTM Call Options Risk. The Fund’s strategy is subject to potential losses if the underlying reference asset increases in value, which may not be offset by the purchase of out-of-the-money (OTM) call options. The Fund purchases OTM calls to seek to manage (cap) the Fund’s potential losses from the Fund’s short exposure to the underlying reference asset if it appreciates significantly in value. However, the OTM call options will cap the Fund’s losses only to the extent that the value of the underlying reference asset increases to a level that is at or above the strike level of the purchased OTM call options. Any increase in the value of the underlying reference asset to a level that is below the strike level of the purchased OTM call options will result in a corresponding loss for the Fund. For example, if the OTM call options have a strike level that is approximately 100% above the then-current value of the underlying reference asset at the time of the call option purchase, and the value of the underlying reference asset increases by at least 100% during the term of the purchased OTM call options, the Fund will lose all its value. Since the Fund bears the costs of purchasing the OTM calls, such costs will decrease the Fund’s value and/or any income otherwise generated by the Fund’s investment strategy.

    Counterparty Risk. The Fund is subject to counterparty risk by virtue of its investments in options contracts. Transactions in some types of derivatives, including options, are required to be centrally cleared (“cleared derivatives”). In a transaction involving cleared derivatives, the Fund’s counterparty is a clearing house rather than a bank or broker. Since the Fund is not a member of clearing houses and only members of a clearing house (“clearing members”) can participate directly in the clearing house, the Fund will hold cleared derivatives through accounts at clearing members.

    Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. The Fund’s investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, imperfect correlation with underlying investments or the Fund’s other portfolio holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions.

    Options Contracts. The use of options contracts involves investment strategies and risks different from those associated with ordinary portfolio securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying reference asset, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events.

    Distribution Risk. As part of the Fund’s investment objective, the Fund seeks to provide current income. There is no assurance that the Fund will make a distribution in any given period. If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

    High Portfolio Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings.

    Liquidity Risk. Some securities held by the Fund, including options contracts, may be difficult to sell or be illiquid, particularly during times of market turmoil.

    Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund.

    New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

    Price Participation Risk. The Fund employs an investment strategy that includes the sale of put option contracts, which limits the degree to which the Fund will participate in decreases in value experienced by the underlying reference asset over the Put Period.

    Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally. The value of the Fund, for any Fund that focuses on an individual security (e.g., TSLA, COIN, NVDA, MSTR), may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole.

    Inflation Risk. Inflation risk is the risk that the value of assets or income from investments will be less in the future as inflation decreases the value of money. As inflation increases, the present value of the Fund’s assets and distributions, if any, may decline.

    Risk Disclosures (applicable only to CHPY)

    Semiconductor Industry Risk. Semiconductor companies may face intense competition, both domestically and internationally, and such competition may have an adverse effect on their profit margins. Semiconductor companies may have limited product lines, markets, financial resources or personnel. Semiconductor companies’ supply chain and operations are dependent on the availability of materials that meet exacting standards and the use of third parties to provide components and services.

    The products of semiconductor companies may face obsolescence due to rapid technological developments and frequent new product introduction, unpredictable changes in growth rates and competition for the services of qualified personnel. Capital equipment expenditures could be substantial, and equipment generally suffers from rapid obsolescence. Companies in the semiconductor industry are heavily dependent on patent and intellectual property rights. The loss or impairment of these rights would adversely affect the profitability of these companies.

    Risk Disclosures (applicable only to YQQQ)

    Index Overview. The Nasdaq 100 Index is a benchmark index that includes 100 of the largest non-financial companies listed on the Nasdaq Stock Market, based on market capitalization.

    Index Level Appreciation Risk. As part of the Fund’s synthetic covered put strategy, the Fund purchases and sells call and put option contracts that are based on the Index level. This strategy subjects the Fund to certain of the same risks as if it shorted the Index, even though it does not. By virtue of the Fund’s indirect inverse exposure to changes in the Index level, the Fund is subject to the risk that the Index level increases. If the Index level increases, the Fund will likely lose value and, as a result, the Fund may suffer significant losses. The Fund may also be subject to the following risks: innovation and technological advancement; strong market presence of Index constituent companies; adaptability to global market trends; and resilience and recovery potential.

    Index Level Participation Risk. The Fund employs an investment strategy that includes the sale of put option contracts, which limits the degree to which the Fund will benefit from decreases in the Index level experienced over the Put Period. This means that if the Index level experiences a decrease in value below the strike level of the sold put options during a Put Period, the Fund will likely not experience that increase to the same extent and any Fund gains may significantly differ from the level of the Index losses over the Put Period. Additionally, because the Fund is limited in the degree to which it will participate in decreases in value experienced by the Index level over each Put Period, but has significant negative exposure to any increases in value experienced by the Index level over the Put Period, the NAV of the Fund may decrease over any given period. The Fund’s NAV is dependent on the value of each options portfolio, which is based principally upon the inverse of the performance of the Index level. The Fund’s ability to benefit from the Index level decreases will depend on prevailing market conditions, especially market volatility, at the time the Fund enters into the sold put option contracts and will vary from Put Period to Put Period. The value of the options contracts is affected by changes in the value and dividend rates of component companies that comprise the Index, changes in interest rates, changes in the actual or perceived volatility of the Index and the remaining time to the options’ expiration, as well as trading conditions in the options market. As the Index level changes and time moves towards the expiration of each Put Period, the value of the options contracts, and therefore the Fund’s NAV, will change. However, it is not expected for the Fund’s NAV to directly inversely correlate on a day-to-day basis with the returns of the Index level. The amount of time remaining until the options contract’s expiration date affects the impact that the value of the options contracts has on the Fund’s NAV, which may not be in full effect until the expiration date of the Fund’s options contracts. Therefore, while changes in the Index level will result in changes to the Fund’s NAV, the Fund generally anticipates that the rate of change in the Fund’s NAV will be different than the inverse of the changes experienced by the Index level.

    YieldMax® ETFs are distributed by Foreside Fund Services, LLC. Foreside is not affiliated with Tidal Financial Group, or YieldMax® ETFs.

    © 2025 YieldMax® ETFs

    The MIL Network